<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65836</article-id><article-id pub-id-type="doi">10.7554/eLife.65836</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-218970"><name><surname>Sabnis</surname><given-names>Akshay</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218957"><name><surname>Hagart</surname><given-names>Katheryn LH</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218971"><name><surname>Klöckner</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218972"><name><surname>Becce</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218973"><name><surname>Evans</surname><given-names>Lindsay E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188661"><name><surname>Furniss</surname><given-names>R Christopher D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5806-5099</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171148"><name><surname>Mavridou</surname><given-names>Despoina AI</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218961"><name><surname>Murphy</surname><given-names>Ronan</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-56610"><name><surname>Stevens</surname><given-names>Molly M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7335-266X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218963"><name><surname>Davies</surname><given-names>Jane C</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-155801"><name><surname>Larrouy-Maumus</surname><given-names>Gérald J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-218974"><name><surname>Clarke</surname><given-names>Thomas B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-218965"><name><surname>Edwards</surname><given-names>Andrew M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7173-7355</contrib-id><email>a.edwards@imperial.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>MRC Centre for Molecular Bacteriology and Infection, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Department of Bioengineering, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>Department of Materials, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution>Institute of Biomedical Engineering, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution>Department of Chemistry, Imperial College London, Molecular Sciences Research Hub</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>Department of Molecular Biosciences, University of Texas at Austin</institution><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>National Heart and Lung Institute, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution>Department of Paediatric Respiratory Medicine, Royal Brompton Hospital</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cole</surname><given-names>Philip A</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cole</surname><given-names>Philip A</given-names></name><role>Senior Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>06</day><month>04</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e65836</elocation-id><history><date date-type="received" iso-8601-date="2020-12-16"><day>16</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-03-31"><day>31</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Sabnis et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Sabnis et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65836-v2.pdf"/><abstract><p>Colistin is an antibiotic of last resort, but has poor efficacy and resistance is a growing problem. Whilst it is well established that colistin disrupts the bacterial outer membrane (OM) by selectively targeting lipopolysaccharide (LPS), it was unclear how this led to bacterial killing. We discovered that MCR-1 mediated colistin resistance in <italic>Escherichia coli</italic> is due to modified LPS at the cytoplasmic rather than OM. In doing so, we also demonstrated that colistin exerts bactericidal activity by targeting LPS in the cytoplasmic membrane (CM). We then exploited this information to devise a new therapeutic approach. Using the LPS transport inhibitor murepavadin, we were able to cause LPS accumulation in the CM of <italic>Pseudomonas aeruginosa</italic>, which resulted in increased susceptibility to colistin in vitro and improved treatment efficacy in vivo. These findings reveal new insight into the mechanism by which colistin kills bacteria, providing the foundations for novel approaches to enhance therapeutic outcomes.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Antibiotics are life-saving medicines, but many bacteria now have the ability to resist their effects. For some infections, all frontline antibiotics are now ineffective. To treat infections caused by these highly resistant bacteria, clinicians must use so-called ‘antibiotics of last resort’. These antibiotics include a drug called colistin, which is moderately effective, but often fails to eradicate the infection. One of the challenges to making colistin more effective is that its mechanism is poorly understood.</p><p>Bacteria have two layers of protection against the outside world: an outer cell membrane and an inner cell membrane. To kill them, colistin must punch holes in both. First, it disrupts the outer membrane by interacting with molecules called lipopolysaccharides. But how it disrupts the inner membrane was unclear. Bacteria have evolved several different mechanisms that make them resistant to the effects of colistin. Sabnis et al. reasoned that understanding how these mechanisms protected bacteria could reveal how the antibiotic works to damage the inner cell membrane.</p><p>Sabnis et al. examined the effects of colistin on <italic>Escherichia coli</italic> bacteria with and without resistance to the antibiotic. Exposing these bacteria to colistin revealed that the antibiotic damages both layers of the cell surface in the same way, targeting lipopolysaccharide in the inner membrane as well as the outer membrane.</p><p>Next, Sabnis et al. used this new information to make colistin work better. They found that the effects of colistin were magnified when it was combined with the experimental antibiotic murepavadin, which caused lipopolysaccharide to build up at the inner membrane. This allowed colistin to punch more holes through the inner membrane, making colistin more effective at killing bacteria. To find out whether this combination of colistin and murepavadin could work as a clinical treatment, Sabnis et al. tested it on mice with <italic>Pseudomonas aeruginosa</italic> infections in their lungs. Colistin was much better at killing <italic>Pseudomonas aeruginosa</italic> and treating infections when combined with murepavadin than it was on its own.</p><p><italic>Pseudomonas aeruginosa</italic> bacteria can cause infections in the lungs of people with cystic fibrosis. At the moment, patients receive colistin in an inhaled form to treat these infections, but it is not always successful. The second drug used in this study, murepavadin, is about to enter clinical trials as an inhaled treatment for lung infections too. If the trial is successful, it may be possible to use both drugs in combination to treat lung infections in people with cystic fibrosis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Polymyxin</kwd><kwd>Colistin</kwd><kwd>lipopolysaccharide</kwd><kwd>phospholipids</kwd><kwd>Pseudomonas</kwd><kwd><italic>E. coli</italic></kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>PhD Studentship</award-id><principal-award-recipient><name><surname>Sabnis</surname><given-names>Akshay</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>KL3191/1</award-id><principal-award-recipient><name><surname>Klöckner</surname><given-names>Anna</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007601</institution-id><institution>Horizon 2020</institution></institution-wrap></funding-source><award-id>838183</award-id><principal-award-recipient><name><surname>Klöckner</surname><given-names>Anna</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000833</institution-id><institution>Rosetrees Trust</institution></institution-wrap></funding-source><award-id>M300-CD1</award-id><principal-award-recipient><name><surname>Becce</surname><given-names>Michele</given-names></name><name><surname>Stevens</surname><given-names>Molly M</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>(MR/M009505/1)</award-id><principal-award-recipient><name><surname>Furniss</surname><given-names>R Christopher D</given-names></name><name><surname>Mavridou</surname><given-names>Despoina AI</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000292</institution-id><institution>Cystic Fibrosis Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Murphy</surname><given-names>Ronan</given-names></name><name><surname>Davies</surname><given-names>Jane C</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>105603/Z/14/Z</award-id><principal-award-recipient><name><surname>Larrouy-Maumus</surname><given-names>Gérald J</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>107660/Z/15Z</award-id><principal-award-recipient><name><surname>Clarke</surname><given-names>Thomas B</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>204337/Z/16/Z</award-id><principal-award-recipient><name><surname>Evans</surname><given-names>Lindsay E</given-names></name><name><surname>Edwards</surname><given-names>Andrew M</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution>NIHR Biomedical Research Centre (Imperial College)</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Davies</surname><given-names>Jane C</given-names></name><name><surname>Edwards</surname><given-names>Andrew M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Modulation of cytoplasmic lipopolysaccharide levels sensitises bacteria to polymyxin antibiotics, revealing a novel combination therapeutic approach.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The emergence of multi-drug-resistant Gram-negative pathogens such as <italic>Escherichia coli</italic>, <italic>Klebsiella pneumoniae</italic> and <italic>Pseudomonas aeruginosa</italic> has led to the increased use of polymyxin antibiotics, which are often the only viable last-resort therapeutic option (<xref ref-type="bibr" rid="bib74">Velkov et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Garg et al., 2017</xref>; <xref ref-type="bibr" rid="bib9">Biswas et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Thomas et al., 2019</xref>). Two closely related polymyxin antibiotics are used clinically, colistin (polymyxin E) and polymyxin B, which share a high degree of structural similarity, consisting of a cationic peptide ring of 7 amino acids connected to a hydrophobic acyl tail by a linear chain of three amino acids (<xref ref-type="bibr" rid="bib74">Velkov et al., 2010</xref>; <xref ref-type="bibr" rid="bib9">Biswas et al., 2012</xref>).</p><p>Polymyxins are rapidly bactericidal towards Gram-negative bacteria in vitro but are considerably less efficacious in vivo, with up to 70% of patients failing to respond to colistin treatment (<xref ref-type="bibr" rid="bib23">Falagas et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Paul et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Linden et al., 2003</xref>). Restrictions on dosage due to the nephrotoxicity of polymyxins mean that only 50% of people with normal renal function achieve a steady state serum concentration sufficient to kill bacteria (<xref ref-type="bibr" rid="bib72">Tran et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Satlin et al., 2020</xref>). As such, there is a desperate need to develop new approaches to enhance the efficacy of polymyxin antibiotics.</p><p>Barriers to increasing polymyxin efficacy include the significant gaps in our understanding of their mode of action. Whilst it is well established that the binding of polymyxins to lipopolysaccharide (LPS) on the surface of Gram-negative bacteria leads to disruption of the outer membrane (OM), it is unclear how this results in cell lysis and bacterial death (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib9">Biswas et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>). It is hypothesised that damage to the LPS monolayer enables polymyxins to traverse the OM via a process of ‘self-directed uptake’, although this has not been demonstrated experimentally (<xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Powers and Hancock, 2003</xref>). Once across the OM, polymyxins permeabilise the cytoplasmic membrane (CM), which is required for bacterial lysis and killing (<xref ref-type="bibr" rid="bib74">Velkov et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Garg et al., 2017</xref>; <xref ref-type="bibr" rid="bib9">Biswas et al., 2012</xref>). However, the mechanism by which colistin damages the CM is unclear (<xref ref-type="bibr" rid="bib62">Powers and Hancock, 2003</xref>; <xref ref-type="bibr" rid="bib73">Trimble et al., 2016</xref>). It has been proposed that the surfactant activity of polymyxins, conferred by the positively charged peptide ring and hydrophobic tail, is sufficient to compromise the phospholipid bilayer of the CM via a detergent-like effect (<xref ref-type="bibr" rid="bib74">Velkov et al., 2010</xref>; <xref ref-type="bibr" rid="bib9">Biswas et al., 2012</xref>). In support of this, polymyxins can interact with mammalian cell membranes, leading to changes in epithelial monolayer permeability (<xref ref-type="bibr" rid="bib6">Berg et al., 1996</xref>). Polymyxin antibiotics also have some inhibitory activity against the Gram-positive bacterium <italic>Streptococcus pyogenes</italic>, where the CM is formed of a phospholipid bilayer (<xref ref-type="bibr" rid="bib8">Betts et al., 2016</xref>).</p><p>However, several lines of evidence call into doubt the ability of physiologically relevant concentrations of polymyxins to disrupt phospholipid bilayers. Firstly, the concentrations of polymyxin B required to disrupt mammalian epithelial cells or inhibit the growth of <italic>S. pyogenes</italic> (8–16 µg ml<sup>−1</sup>) are above typical serum concentrations of the antibiotic, and colistin at clinically relevant concentrations displays no activity against other Gram-positive organisms such as <italic>Staphylococcus aureus</italic> or <italic>Enterococcus faecalis</italic> (<xref ref-type="bibr" rid="bib6">Berg et al., 1996</xref>; <xref ref-type="bibr" rid="bib8">Betts et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Si et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">Kouidhi et al., 2011</xref>). Furthermore, colistin has very little activity against synthetic phospholipid bilayer membranes unless LPS is present, a finding that explains why polymyxins are 30–100-fold less active against colistin-resistant <italic>Acinetobacter baumanii</italic> isolates that are LPS-deficient, with an OM composed of a phospholipid bilayer (<xref ref-type="bibr" rid="bib35">Khadka et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Moffatt et al., 2010</xref>; <xref ref-type="bibr" rid="bib81">Zhang et al., 2018</xref>). Finally, molecular dynamics simulations show that the interaction of colistin with phospholipid bilayers is unlike what has been reported for other antimicrobial peptides that target phospholipid bilayers (<xref ref-type="bibr" rid="bib25">Fu et al., 2020</xref>). Together, these observations call into question whether, at physiologically relevant concentrations, colistin disrupts the CM of Gram-negative bacteria via the engagement of the polymyxin antibiotic with membrane phospholipids.</p><p>In addition to the mode of action of colistin, there are also gaps in our understanding of the mechanisms by which colistin resistance protects bacteria from polymyxin antibiotics. In Gram-negative bacteria, LPS is synthesised in the cytoplasm via the Raetz pathway, during which it is introduced into the inner leaflet of the CM (<xref ref-type="bibr" rid="bib63">Raetz et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Simpson and Trent, 2019</xref>). It is then flipped to the outer leaflet of the CM by MsbA before transportation to the OM via the LptABCDEFG machinery (<xref ref-type="bibr" rid="bib56">Okuda et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Zhou et al., 1998</xref>; <xref ref-type="bibr" rid="bib41">Li et al., 2019</xref>). To date, 10 mobile colistin resistance (<italic>mcr</italic>) gene variants have been described, all of which encode phosphoethanolamine (pEtN) transferases that modify the lipid A component of LPS with pEtN as it is trafficked through the CM on the way to the OM (<xref ref-type="bibr" rid="bib44">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib13">Carroll et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Nang et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Skov and Monnet, 2016</xref>; <xref ref-type="bibr" rid="bib75">Wang et al., 2020</xref>). Colistin resistance can also arise via mutations in genes encoding two-component regulatory systems such as PhoPQ, PmrAB, or BasRS (<xref ref-type="bibr" rid="bib60">Poirel et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Janssen et al., 2020</xref>). This typically leads to the addition of 4-amino-4-deoxy-l-arabinose (L-ara4N) and/or pEtN groups to LPS, with this modification also occurring at the CM (<xref ref-type="bibr" rid="bib66">Simpson and Trent, 2019</xref>; <xref ref-type="bibr" rid="bib60">Poirel et al., 2017</xref>).</p><p>Despite the association between MCR-mediated LPS modification and colistin resistance, there is evidence that it does not prevent polymyxin-mediated damage of the OM. For example, colistin has been shown to permit ingress of the <italic>N</italic>-phenyl-1-napthylamine (NPN) fluorophore into the OM of <italic>E. coli</italic> expressing <italic>mcr</italic>-1 (<xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>). Furthermore, colistin greatly enhances the activity of hydrophobic antibiotics such as rifampicin against polymyxin-resistant bacteria via disruption of the OM (<xref ref-type="bibr" rid="bib10">Brennan-Krohn et al., 2018</xref>). However, despite colistin damaging the OM of resistant bacteria, it is unable to kill or lyse them (<xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>). This suggests that the modification of LPS with pEtN and/or L-ara4N protects the CM from colistin, but it is not clear how (<xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>; <xref ref-type="bibr" rid="bib10">Brennan-Krohn et al., 2018</xref>).</p><p>Improving our knowledge of how colistin kills bacteria is essential to help devise new approaches to enhance the efficacy of last resort polymyxin antibiotics (<xref ref-type="bibr" rid="bib44">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib13">Carroll et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Nang et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Skov and Monnet, 2016</xref>; <xref ref-type="bibr" rid="bib75">Wang et al., 2020</xref>). To do this, we set out to better understand how <italic>mcr</italic>-1 protects bacteria from colistin and to then use this information to elucidate the mode of action of colistin, with the ultimate aim of exploiting this information to improve colistin efficacy.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MCR-1 protects the CM but not the OM from colistin-mediated disruption</title><p>The first issue we wanted to resolve was whether MCR-1 protected the CM and/or OM of bacteria from colistin. To do this, we used an isogenic <italic>E. coli</italic> MC1000 strain pair, one of which expresses <italic>mcr</italic>-1 from the IPTG-inducible vector pDM1 (<italic>mcr</italic>-1) to ensure consistent expression under our experimental conditions, and the other transformed with the pDM1 vector alone as a control (pEmpty) (<xref ref-type="bibr" rid="bib21">Dortet et al., 2018</xref>; Key resources table). As expected, we found that <italic>E. coli</italic> MC1000 expressing <italic>mcr-1</italic> had a significantly greater colistin minimum inhibitory concentration (MIC, 2 µg ml<sup>−1</sup>) compared to the MC1000 pEmpty control strain (0.25 µg ml<sup>−1</sup>), which was similar to that seen for clinical isolates (<xref ref-type="bibr" rid="bib21">Dortet et al., 2018</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). This confirmed that the <italic>E. coli</italic> cells were producing functional MCR-1.</p><p>To fully characterise the LPS-modifying activity of MCR-1, we undertook MALDI-TOF-based lipidomic analysis of both whole <italic>E. coli</italic> cells and <italic>E. coli</italic> spheroplasts that lacked an OM (<xref ref-type="bibr" rid="bib76">Weiss and Fraser, 1973</xref>). We confirmed spheroplast formation by microscopy and used FITC labelling of OM surface proteins to demonstrate removal of the OM (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Our lipidomic analysis revealed the presence of LPS modified with pEtN in both the CM and OM of <italic>mcr</italic>-1 expressing bacteria, consistent with the location of MCR-1 in the CM (<xref ref-type="bibr" rid="bib21">Dortet et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Furniss et al., 2019</xref>; <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Of note, whilst 42 ± 19% of total cellular LPS from MCR-1-producing <italic>E. coli</italic> was unmodified, the proportion of unmodified LPS in the CM was just 21 ± 2% (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Colistin disrupts the outer membrane but not the cytoplasmic membrane of <italic>E. coli</italic> expressing <italic>mcr-1</italic>.</title><p>(<bold>A</bold>) Quantification of LPS modified with phosphoethanolamine, expressed as the percentage of unmodified lipid A and unmodified lipid A, in whole cells and spheroplasts of <italic>E. coli</italic> MC1000 expressing <italic>mcr-1</italic>, as determined by MALDI-TOF-based lipidomics (n = 3 in duplicate, *p&lt;0.05 between Whole Cells and Spheroplasts). (<bold>B</bold>) OM disruption of <italic>E. coli</italic> MC1000 cells expressing <italic>mcr-1</italic> or an empty plasmid control strain (pEmpty) during 10 min of exposure to colistin at the indicated antibiotic concentrations, as determined by uptake of the fluorescent dye NPN (10 µM) (n = 5, each data point represents the arithmetic mean of 20 replicate measurements; ns: p&gt;0.05 between pEmpty and <italic>mcr-1</italic> strains, *p&lt;0.05 between the indicated concentrations of colistin). (<bold>C</bold>) Permeabilisation of the CM of <italic>E. coli</italic> MC1000 cells expressing <italic>mcr-1</italic> or empty plasmid-containing cells during incubation with colistin (4 µg ml<sup>−1</sup>), as determined using 2.5 µM propidium iodide (PI) (n = 4; *p&lt;0.0001 between pEmpty and <italic>mcr-1</italic> strains). (<bold>D</bold>) Growth or lysis of <italic>E. coli</italic> MC1000 cells expressing <italic>mcr-1</italic> or empty plasmid control cells during exposure to colistin (4 µg ml<sup>−1</sup>), as measured using OD<sub>595nm</sub> readings (n = 4; *p&lt;0.05 between pEmpty and <italic>mcr-1</italic> strains). Data in (<bold>A</bold>) were analysed by a two-tailed paired Student’s <italic>t</italic>-test. Data in (<bold>B–D</bold>) were analysed by a two-way ANOVA with Sidak’s (<bold>B</bold>) or Dunnett’s (<bold>C, D</bold>) post hoc tests. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean. OM: outer membrane; NPN: <italic>N</italic>-phenyl-1-naphthylamine; CM: cytoplasmic membrane; r.f.u.: relative fluorescence units; OD: optical density.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Colistin causes outer membrane (OM) disruption, but the process by which this leads to cytoplasmic membrane (CM) damage and bacterial lysis is not known.</title><p>Diagrammatic representation of the current hypothesised mechanism of action of colistin: (1) Colistin binds to LPS in the OM, causing displacement of cations that form bridges between LPS molecules and leading to membrane disruption. (2) The antibiotic then crosses the OM via a process termed ‘self-directed uptake’. (3) Colistin subsequently disrupts the CM through a mechanism that remains unclear. (4, 5) Once the cell envelope is permeabilised, the bacteria lyse and are killed.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Characterisation of the <italic>E. coli</italic> MC1000 strain harbouring a plasmid encoding the colistin resistance gene <italic>mcr-1</italic>, and an MC1000 strain containing the pDM1 plasmid only (pEmpty) as a control strain.</title><p>(<bold>A</bold>) Growth of <italic>E. coli</italic> MC1000 cells containing an empty pDM1 plasmid (pEmpty) or MC1000 cells containing the pDM1 plasmid expressing the <italic>mcr-1</italic> gene, as determined by measuring OD<sub>600nm</sub> over 16 hr incubation at 37°C (n = 3 in triplicate). (<bold>B</bold>) Final growth densities of <italic>E. coli</italic> MC1000 cells with an empty pDM1 plasmid and MC1000 cells harbouring the pDM1 plasmid encoding the <italic>mcr-1</italic> gene in MHB media containing the indicated concentrations of colistin, as determined by measuring OD<sub>595nm</sub> after 18 hr incubation (n = 3 in triplicate; *p&lt;0.0001 compared to pEmpty strain). Expression of the mobilised colistin resistance determinant <italic>mcr-1</italic> by <italic>E. coli</italic> MC1000 bacteria resulted in only a minor growth defect relative to empty plasmid-containing control cells (<bold>A</bold>). As expected, <italic>E. coli</italic> MC1000 cells producing MCR-1 had an eightfold increase in the MIC of colistin in comparison to the isogenic empty plasmid strain (2 μg ml<sup>−1</sup> versus 0.25 μg ml<sup>−1</sup>) (<bold>B</bold>). This confirmed that the bacteria harbouring a plasmid with the <italic>mcr-1</italic> gene were resistant to colistin. Data in <bold>B</bold> were analysed by a two-way ANOVA with Sidak’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Formation of <italic>E. coli</italic> pEmpty and <italic>mcr-1</italic> spheroplasts.</title><p>(<bold>A</bold>) Representative phase contrast micrographs of <italic>E. coli</italic> MC1000 cells harbouring an empty pDM1 plasmid (pEmpty) or a pDM1 plasmid expressing the colistin-resistance determinant <italic>mcr-1</italic> before (<italic>Whole Cells</italic>) and after (<italic>Spheroplasts</italic>) treatment with 0.25 mg ml<sup>−1</sup> EDTA (to remove the outer membrane [OM]) and 1 mg ml<sup>−1</sup> lysozyme (to remove the cell wall) for 1 hr at 30°C, followed by the addition of trypsin (0.5 mg ml<sup>−1</sup>) for 15 min, with all incubations occurring in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose (Scale bars: 5 μm). (<bold>B</bold>) Quantification of length:width ratio of <italic>E. coli</italic> MC1000 cells containing an empty plasmid, or <italic>E. coli</italic> cells with the same plasmid encoding the <italic>mcr-1</italic> gene, before (<italic>Whole Cells</italic>) and after (<italic>Spheroplasts</italic>) exposure to EDTA, lysozyme and trypsin (<bold>A</bold>) (n = 100 cells per group; *p&lt;0.0001 compared to the respective Whole Cells). Removal of the OM and cell wall from both <italic>E. coli</italic> MC1000 pEmpty and <italic>mcr-1</italic>-expressing bacteria results in the formation of round cells with a length:width ratio of ~1 (<bold>A, B</bold>), confirming the successful production of <italic>E. coli</italic> spheroplasts lacking the OM and cell wall. Data in <bold>B</bold> were analysed by a one-way ANOVA with Tukey’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Conversion of <italic>E. coli</italic> whole cells to spheroplasts results in removal of the OM, and no OM contamination in the CM.</title><p>(<bold>A</bold>) Representative fluorescence microscopy images of <italic>E. coli</italic> MC1000 pEmpty cells labelled with fluorescein isothiocyanate (FITC, 0.5 mg ml<sup>−1</sup>) before (<italic>Whole Cells</italic>) and after (<italic>Spheroplasts</italic>) conversion to spheroplasts with EDTA (0.25 mg ml<sup>−1</sup>) and lysozyme (1 mg ml<sup>−1</sup>) in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose, as described in <xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref> (Scale bars: 5 μm). (<bold>B</bold>) Quantification of fluorescence from FITC-labelled <italic>E. coli</italic> MC1000 pEmpty cells before (<italic>Whole Cells</italic>) and after (<italic>Spheroplasts</italic>) conversion to spheroplasts (n = 3 in triplicate; *p&lt;0.01 compared to Whole Cells). Proteins in the OM of whole <italic>E. coli</italic> MC1000 cells were tagged with a FITC fluorophore for 30 min, as previously described (<xref ref-type="bibr" rid="bib77">Wiegand et al., 2008</xref>). Following conversion of these labelled bacterial cells to spheroplasts, there was virtually no fluorescence from FITC visible by microscopy (<bold>A</bold>), or when quantifying the entire cell population (<bold>B</bold>). This confirmed that the OM had been successfully removed during the formation of spheroplasts, and that there was no contamination of the CM with material from the OM. Data in <bold>B</bold> were analysed by a paired Student’s <italic>t</italic>-test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>The ratio of modified lipid A to unmodified lipid A is significantly greater in the cytoplasmic membrane (CM) than in the outer membrane (OM) of <italic>E. coli</italic> expressing <italic>mcr-1</italic>.</title><p>Representative mass spectra showing the ratio of unmodified lipid A (red) to lipid A modified with phosphoethanolamine (blue) in whole cells and spheroplasts of <italic>E. coli</italic> MC1000 expressing <italic>mcr-1</italic>, as determined by MALDI-TOF-based lipidomics. There was a higher proportion of LPS modified with pETN in <italic>mcr-1</italic>-expressing <italic>E. coli</italic> MC1000 spheroplasts compared to whole <italic>E. coli</italic> MC1000 cells, demonstrating that there is an increased abundance of unmodified LPS in the OM compared to the CM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig1-figsupp5-v2.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title>Colistin potentiates the activity of rifampicin against colistin-resistant <italic>E. coli</italic> expressing <italic>mcr-1</italic>.</title><p>Checkerboard broth microdilution assay showing the synergistic growth-inhibitory activity of colistin and rifampicin against <italic>E. coli</italic> MC1000 cells producing MCR-1, as determined by measuring OD<sub>600nm</sub> after 18 hr incubation. Gram-negative bacteria including <italic>E. coli</italic> are intrinsically resistant to rifampicin, due to its inability to penetrate the OM of the cell envelope and access its intracellular target (<xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>). However, colistin and rifampicin displayed potent synergy against <italic>mcr-1</italic>-expressing <italic>E. coli</italic>, with a fractional inhibitory concentration index (FICI) value of 0.14. This indicated that colistin was enabling rifampicin to cross the OM and enter the cytoplasm, providing further evidence that colistin was able to disrupt the OM of resistant bacteria producing MCR-1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig1-figsupp6-v2.tif"/></fig></fig-group><p>We next assessed the effect of colistin on the integrity of the <italic>E. coli</italic> OM using the hydrophobic NPN dye, which fluoresces upon contact with phospholipids exposed by damage to the LPS monolayer (<xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Helander and Mattila-Sandholm, 2000</xref>). As expected, colistin caused permeabilisation of the OM of the <italic>E. coli</italic> pEmpty strain in a dose-dependent manner (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In agreement with previous findings, we found that colistin also disrupted the OM of <italic>E. coli</italic> expressing <italic>mcr</italic>-1 to a similar degree to <italic>E. coli</italic> pEmpty (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>). To further investigate permeabilisation of the OM by colistin, we assessed the susceptibility of bacteria to rifampicin in the presence of the polymyxin antibiotic. Rifampicin cannot normally cross the OM, which makes <italic>E. coli</italic> intrinsically resistant to the antibiotic. However, in keeping with previous work, we found that colistin sensitised <italic>E. coli</italic> expressing <italic>mcr-1</italic> to rifampicin, with a fractional inhibitory concentration index (FICI) value of 0.14 indicating synergy between the two antibiotics in a checkerboard assay (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>; <xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>). This confirmed that colistin disrupted the OM of resistant bacteria producing MCR-1. Therefore, MCR-1-mediated changes to LPS did not prevent permeabilisation of the OM by colistin, which reflects the presence of the relatively large quantity of unmodified LPS in the OM as determined in our lipidomic analysis (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>).</p><p>Next, we assessed damage to the CM structure in the <italic>E. coli</italic> strain pair during colistin exposure, using the membrane impermeant dye propidium iodide (PI). PI fluoresces upon contact with DNA in the bacterial cytoplasm, and thus is indicative of permeabilisation of the both the OM and CM of whole bacterial cells (<xref ref-type="bibr" rid="bib2">Allison and Lambert, 2015</xref>; <xref ref-type="bibr" rid="bib59">Pietschmann et al., 2009</xref>). As expected, colistin exposure resulted in a strong PI signal from <italic>E. coli</italic> pEmpty cells, indicative of CM permeabilisation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), which gradually declined, most likely due to nucleases released from lysed bacteria (<xref ref-type="bibr" rid="bib39">Lee et al., 2017</xref>). However, despite colistin permeabilising the OM of <italic>E. coli</italic> expressing <italic>mcr</italic>-1, the CM of these bacteria remained intact, as demonstrated by the lack of PI-mediated fluorescence (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In keeping with these findings, colistin caused lysis of <italic>E. coli</italic> pEmpty cells, as seen by a reduction in OD<sub>595nm</sub> readings over time (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). By contrast, <italic>E. coli</italic> cells producing MCR-1 grew in the presence of colistin despite the damage the polymyxin caused to the OM, as demonstrated by an increase in OD<sub>595nm</sub> measurements over time (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). As such, the damage caused to the OM of <italic>E. coli</italic> MCR-1 strain by colistin is likely to be minor.</p><p>Taken together, these data demonstrate that MCR-1 protects the CM but not the OM from colistin-mediated permeabilisation.</p></sec><sec id="s2-2"><title>Colistin targets LPS in the CM</title><p>Although colistin was able to permeabilise the OM of <italic>E. coli</italic> expressing <italic>mcr</italic>-1, it was possible that the pEtN modifications might reduce the ability of the antibiotic to access the periplasm and thus the CM. To negate this possibility and focus on whether MCR-1 mediated LPS modification directly protected the CM from colistin, we performed experiments using spheroplasts of our <italic>E. coli</italic> strains that lacked both OM and cell wall.</p><p>To test whether LPS modifications altered the biophysical properties of the CM, we measured both membrane fluidity and surface charge of the <italic>E. coli</italic> spheroplasts using established methods. There were no differences in fluidity of the CM between <italic>E. coli</italic> pEmpty or <italic>mcr-1-</italic>expressing cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). As might be expected, there was a slight increase in the positive charge of the CM of the <italic>mcr-1</italic>-expressing <italic>E. coli</italic> relative to the pEmpty control, indicative of the presence of cationic pEtN modifications to LPS (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). To investigate whether this slight increase in membrane positivity was likely to be sufficient to repel colistin from the membrane, we determined the susceptibility of spheroplasts from <italic>E. coli</italic> MC1000 <italic>mcr</italic>-1 or pEmpty to colistin and compared it with the cationic antimicrobial peptides (CAMPs) daptomycin or nisin. Both CAMPs are well characterised for their ability to permeabilise phospholipid bilayers and, like colistin, they are positively charged, enabling us to detect whether the change to membrane charge conferred by MCR-1-modified LPS in the CM contributed specifically to polymyxin resistance (<xref ref-type="bibr" rid="bib34">Karas et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Zendo et al., 2010</xref>). Importantly, increased membrane positive charge is a common mechanism of resistance to daptomycin (<xref ref-type="bibr" rid="bib34">Karas et al., 2020</xref>).</p><p>In the absence of treatment, there was a small but progressive loss of CM integrity over time due to the fragile nature of spheroplasts. However, allowing for this, the CM of spheroplasts of <italic>E. coli</italic> MC1000 <italic>mcr</italic>-1 was resistant to damage by colistin, but susceptible to daptomycin and nisin (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>). By contrast, colistin, daptomycin, and nisin all permeabilised the CM of spheroplasts of <italic>E. coli</italic> pEmpty (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>). In keeping with the data from assays measuring CM damage, colistin, daptomycin, and nisin all caused lysis of spheroplasts of <italic>E. coli</italic> pEmpty, whilst the spheroplasts from <italic>E. coli</italic> expressing <italic>mcr-1</italic> were undamaged by colistin, but were lysed by both daptomycin and nisin (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>). Combined, these data demonstrated that the protection afforded to the CM by MCR-1 is specific for colistin, and that the polymyxin antibiotic does not share the same target as the phospholipid-targeting CAMPs.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>MCR-1 protects the cytoplasmic membrane of <italic>E. coli</italic> spheroplasts from colistin but not other cationic antimicrobial peptides.</title><p>(<bold>A–C</bold>) Permeabilisation of the CM of <italic>E. coli</italic> MC1000 spheroplasts generated from bacteria expressing <italic>mcr-1</italic> or empty plasmid control bacteria (pEmpty) during incubation with (<bold>A</bold>) colistin (4 µg ml<sup>−1</sup>), (<bold>B</bold>) daptomycin (20 µg ml<sup>−1</sup>, with 1.25 mM Ca<sup>2+</sup> ions), or (<bold>C</bold>) nisin (20 µg ml<sup>−1</sup>), as determined using 0.25 µM PI (n = 3, experiment performed on four independent occasions; *p&lt;0.01 between pEmpty and <italic>mcr-1</italic> strains). (<bold>D–F</bold>) Lysis of <italic>E. coli</italic> MC1000 spheroplasts generated from bacteria expressing <italic>mcr-1</italic> or empty plasmid control bacteria during incubation with (<bold>D</bold>) colistin (4 µg ml<sup>−1</sup>), (<bold>E</bold>) daptomycin (20 µg ml<sup>−1</sup>, with 1.25 µM Ca<sup>2+</sup> ions), or (<bold>F</bold>) nisin (20 µg ml<sup>−1</sup>), as measured using OD<sub>600nm</sub> readings (n = 3, experiment performed on four independent occasions; *p&lt;0.05 between pEmpty and <italic>mcr-1</italic> strains, error bars are omitted for clarity). Data in (<bold>A–F</bold>) were analysed by a two-way ANOVA with Dunnett’s post hoc test. Data are presented as the arithmetic mean, and error bars, where shown, represent the standard deviation of the mean. CM: cytoplasmic membrane; r.f.u.: relative fluorescence units; OD: optical density.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>LPS modifications in the CM of colistin-resistant <italic>E. coli</italic> expressing <italic>mcr-1</italic> has a small effect on membrane charge but not membrane fluidity.</title><p>(<bold>A</bold>) Fluidity of the CM of <italic>E. coli</italic> MC1000 spheroplasts producing MCR-1 or an empty plasmid control strain, as determined using the fluorescent Laurdan dye (100 µM) to generate Generalised Polarisation (GP) values (n = 3 in duplicate; ns: p&gt;0.05 compared to pEmpty). (<bold>B</bold>) Charge of the CM of <italic>E. coli</italic> MC1000 spheroplasts producing MCR-1 or an empty plasmid control strain, as determined by binding of highly positively charged FITC-labelled Poly-L-Lysine (PLL, 20 µg ml<sup>−1</sup>) to the surface of spheroplasts (n = 3; *p&lt;0.05 compared to pEmpty). There was no difference in GP between pEmpty spheroplasts and spheroplasts expressing <italic>mcr-1</italic>, indicating that modified LPS had no effect on the fluidity of the CM (<bold>A</bold>). As expected, there was a small decrease in the amount of positively-charged PLL that could bind to the CM of spheroplasts producing MCR-1 compared to pEmpty, demonstrating that LPS modifications slightly increased the net positive charge of the CM (<bold>B</bold>). Data in (<bold>A, B</bold>) were analysed by a two-tailed paired Student’s <italic>t</italic>-test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>The amount of unmodified LPS in the CM of colistin-resistant <italic>E. coli</italic> expressing <italic>mcr-1</italic> is proportional to the degree of susceptibility to colistin-mediated CM damage.</title><p>(<bold>A</bold>) Representative mass spectra showing the presence and abundance of unmodified lipid A (red) and lipid A modified with phosphoethanolamine (blue) in MCR-1-producing spheroplasts of <italic>E. coli</italic> MC1000 either uninduced, or induced with 0.05 mM IPTG, as determined by MALDI-TOF-based lipidomics. Also shown, a spectrum from the same analysis of <italic>E. coli</italic> pEmpty (<bold>B</bold>) Quantification of LPS modified with phosphoethanolamine, expressed as the ratio of modified lipid A to unmodified lipid A, in MCR-1-producing spheroplasts of <italic>E. coli</italic> MC1000 either uninduced, or induced with 0.05 mM IPTG, as determined by MALDI-TOF-based lipidomics. (n = 3, *p&lt;0.01 between 0 mM IPTG and 0.05 mM IPTG). (<bold>C</bold>) Permeabilisation by colistin (4 µg ml<sup>−1</sup>) of the CM of <italic>E. coli</italic> MC1000 spheroplasts generated from empty plasmid control bacteria, or from bacteria expressing <italic>mcr-1</italic> either uninduced, or induced with 0.05 mM IPTG, as determined using 0.25 µM PI (n = 3, experiment performed on three independent occasions). (<bold>D</bold>) Lysis by colistin (4 µg ml<sup>−1</sup>) of <italic>E. coli</italic> MC1000 spheroplasts generated from empty plasmid control bacteria, or from bacteria expressing <italic>mcr-1</italic> either uninduced, or induced with 0.05 mM IPTG, as measured using OD<sub>600nm</sub> readings (n = 3, experiment performed on three independent occasions). Spheroplasts of <italic>E. coli</italic> cells producing MCR-1 with different amounts of modified LPS in the CM were generated using the IPTG-inducible pDM1 plasmid. In the absence of IPTG induction, pETN-modified LPS was detected in the CM of <italic>E. coli</italic> spheroplasts, suggesting leakiness of the expression vector (<bold>A</bold>). Crucially, however, there was a significant increase in the proportion of pETN-modified lipid A relative to unmodified lipid A in the CM in response to 0.05 mM IPTG, in keeping with increased <italic>mcr-1</italic> expression (<bold>A, B</bold>). The quantity of unmodified LPS in the CM of <italic>E. coli</italic> spheroplasts correlated with the extent to which the CM was susceptible to colistin-induced disruption of the CM, with spheroplasts that were not induced with IPTG displaying only a partial reduction in PI uptake in response to the polymyxin antibiotic compared to pEmpty spheroplasts (<bold>C</bold>). In keeping with this, colistin-mediated lysis of uninduced spheroplasts producing MCR-1 was delayed, but not prevented (<bold>D</bold>). By contrast, <italic>E. coli</italic> spheroplasts expressing <italic>mcr-1</italic> which were induced with 0.05 mM IPTG and had a lower proportion of unmodified lipid A in the CM and exhibited no CM disruption in response to colistin and there was also no lysis of spheroplasts observed (<bold>C, D</bold>). This confirmed that resistance to colistin conferred by <italic>mcr-1</italic> was directly related to the amount of unmodified LPS present in the CM. Data in <bold>B</bold> were analysed by a one-way ANOVA with Sidak’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig2-figsupp2-v2.tif"/></fig></fig-group><p>To further explore the specificity of MCR-1-mediated LPS modifications in the CM for protection against colistin, we produced spheroplasts of <italic>E. coli</italic> with different levels of LPS modification. This revealed a clear dose-dependent relationship between the abundance of unmodified LPS in the CM and the susceptibility of spheroplasts to colistin-mediated CM damage and lysis (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>Therefore, since MCR-1 specifically modifies LPS and this modification selectively protects the CM from colistin in a dose-dependent manner, we concluded that LPS is the CM target of colistin, just as it is in the OM.</p></sec><sec id="s2-3"><title>Colistin damages the CM by disrupting cation bridges between LPS molecules</title><p>To understand how colistin targeting of LPS in the CM leads to membrane disruption, we studied the role of cation bridges which are crucial for stabilising interactions between LPS molecules, by exposing spheroplasts from <italic>E. coli</italic> pEmpty cells to colistin in the absence or presence of excess magnesium. In keeping with a role for cation bridges, we found that magnesium chloride conferred dose-dependent protection from colistin-mediated CM disruption (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To rule out a general protective osmotic effect from the higher salt concentration, we demonstrated that identical concentrations of sodium chloride did not protect spheroplasts from colistin (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Furthermore, the presence of exogenous magnesium had no significant effect on reducing spheroplast CM damage caused by daptomycin or nisin (<xref ref-type="fig" rid="fig3">Figure 3C,D</xref>), confirming that these CAMPs do not have the same CM target as colistin.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Colistin damages the cytoplasmic membrane by disrupting cation bridges between LPS molecules.</title><p>(<bold>A, B</bold>) Permeabilisation of the CM of <italic>E. coli</italic> MC1000 spheroplasts generated from empty plasmid control bacteria during incubation with colistin (4 µg ml<sup>−1</sup>), in the absence or presence of either MgCl<sub>2</sub>( <bold>A</bold>) or NaCl (<bold>B</bold>) at the indicated concentrations, as determined using 0.25 µM PI (n = 3, experiment performed on three independent occasions; *p&lt;0.01 between 0 mM MgCl<sub>2</sub> and 10 mM MgCl<sub>2</sub>). (<bold>C, D</bold>) Permeabilisation of the CM of <italic>E. coli</italic> MC1000 spheroplasts generated from empty plasmid control bacteria during incubation with either (<bold>C</bold>) daptomycin (20 µg ml<sup>−1</sup>, with 1.25 mM Ca<sup>2+</sup> ions) or (<bold>D</bold>) nisin (20 µg ml<sup>−1</sup>), in the absence or presence of MgCl<sub>2</sub> at the indicated concentrations, as determined using 0.25 µM PI (n = 3, experiment performed on three independent occasions). Data in (<bold>A–D</bold>) were analysed by a two-way ANOVA with Dunnett’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean. CM: cytoplasmic membrane; r.f.u.: relative fluorescence units.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig3-v2.tif"/></fig><p>In conclusion, our findings demonstrate that colistin targets LPS in the CM of polymyxin-susceptible <italic>E. coli</italic>, leading to the displacement of cationic inter-LPS bridges, membrane disruption, and ultimately bacterial lysis. This is similar to the mechanism by which colistin disrupts the OM of bacteria and synthetic phospholipid bilayer membranes containing low levels of LPS (<xref ref-type="bibr" rid="bib35">Khadka et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Moore and Hancock, 1986</xref>; <xref ref-type="bibr" rid="bib19">D'amato et al., 1975</xref>). However, the high levels of LPS modified by pEtN in the CM of MCR-1-producing <italic>E. coli</italic> prevent colistin from targeting LPS in the CM, protecting the membrane and conferring resistance to the polymyxin antibiotic.</p></sec><sec id="s2-4"><title>Murepavadin-triggered LPS accumulation in the CM sensitises <italic>P. aeruginosa</italic> to colistin</title><p>Having determined that colistin kills bacteria by targeting LPS in the CM, we wanted to use this information to develop a new therapeutic approach to enhance colistin efficacy.</p><p>Murepavadin is a first-in-class peptide-based inhibitor of the LptD component of the LptABCDEFG complex of <italic>P. aeruginosa</italic> that transports LPS from the CM to the OM (<xref ref-type="bibr" rid="bib3">Andolina et al., 2018</xref>). Thus, inhibition of the Lpt system in <italic>P. aeruginosa</italic> leads to LPS accumulation in the CM, which we hypothesised would increase the susceptibility of the bacterium to colistin (<xref ref-type="bibr" rid="bib3">Andolina et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Sperandeo et al., 2008</xref>).</p><p>To test our hypothesis, we first used a checkerboard MIC assay and found that colistin synergised with murepavadin against <italic>P. aeruginosa</italic> PA14 cells (FICI value of 0.375), revealing that sub-lethal concentrations of the LptD inhibitor sensitised the bacterium to colistin (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="bibr" rid="bib55">Odds, 2003</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Murepavadin sensitises <italic>P. aeruginosa</italic> to colistin by increasing LPS abundance in the cytoplasmic membrane.</title><p>(<bold>A</bold>) Checkerboard broth microdilution assay showing the synergistic growth-inhibitory interaction between colistin and the LPS transport inhibitor murepavadin against <italic>P. aeruginosa</italic> PA14 cells, as determined by measuring OD<sub>595nm</sub> after 18 hr incubation. (<bold>B</bold>) OM disruption of <italic>P. aeruginosa</italic> PA14 cells during 10 min exposure to colistin (2 µg ml<sup>−1</sup>) in the absence or presence of murepavadin (0.05 µg ml<sup>−1</sup>), as assessed by uptake of the fluorescent dye NPN (10 µM) (n = 4, each data point represents the arithmetic mean of 20 replicate measurements; ns: p&gt;0.05 between colistin-treated bacteria). (<bold>C</bold>) CM disruption of <italic>P. aeruginosa</italic> PA14 cells exposed to colistin (2 µg ml<sup>−1</sup>) in the absence or presence of murepavadin (0.05 µg ml<sup>−1</sup>), as determined using 2.5 µM PI (n = 4; *p&lt;0.0001 for colistin and murepavadin-exposed cells compared to colistin alone). (<bold>D</bold>) Lysis of <italic>P. aeruginosa</italic> PA14 cells exposed to colistin (2 µg ml<sup>−1</sup>) in the absence of presence of murepavadin (0.05 µg ml<sup>−1</sup>), as measured by OD<sub>595nm</sub> readings (n = 4; *p&lt;0.01 for colistin and murepavadin-exposed cells compared to colistin alone). Data in (<bold>B</bold>) were analysed by a one-way ANOVA with Tukey’s post hoc test. Data in (<bold>C, D</bold>) were analysed by a two-way ANOVA with Dunnett’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean. OM: outer membrane; NPN: <italic>N</italic>-phenyl-1-naphthylamine; CM: cytoplasmic membrane; r.f.u.: relative fluorescence units; OD: optical density.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Formation of <italic>P. aeruginosa</italic> spheroplasts.</title><p>(<bold>A, B</bold>) Representative phase contrast micrographs of <italic>P. aeruginosa</italic> PA14 cells before (<bold>A</bold>) and after (<bold>B</bold>) treatment with 0.25 mg ml<sup>−1</sup> EDTA (to remove the OM) and 1 mg ml<sup>−1</sup> lysozyme (to remove the cell wall) for 1 hr at 30°C, followed by the addition of trypsin (0.5 mg ml<sup>−1</sup>) for 15 min, with all incubations occurring in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose (Scale bars: 5 μm). (<bold>C</bold>) Quantification of length:width ratio of <italic>P. aeruginosa</italic> PA14 whole cells (<bold>A</bold>) and <italic>P. aeruginosa</italic> spheroplasts following exposure to EDTA, lysozyme, and trypsin (<bold>B</bold>) (n = 250 cells per group; *p&lt;0.0001 compared to Whole Cells). (<bold>D</bold>) Lysis of <italic>P. aeruginosa</italic> spheroplasts exposed to EDTA (0.25 mg ml<sup>−1</sup>) and lysozyme (1 mg ml<sup>−1</sup>) at 30°C in Tris buffer (0.03 M, pH 8.0), in the presence or absence of 20% sucrose, as determined by OD<sub>595nm</sub> measurements (n = 4; *p&lt;0.0001 compared to No Sucrose). After removal of the OM and cell wall with EDTA and lysozyme respectively, the resulting <italic>P. aeruginosa</italic> cells formed had a length:width ratio of almost exactly 1 (<bold>C</bold>) and immediately lysed when not maintained in an osmoprotective environment containing 20% sucrose (<bold>D</bold>). Together, these data confirmed the successful production of <italic>P. aeruginosa</italic> spheroplasts lacking the OM and cell wall. Data in <bold>C</bold> were analysed by an unpaired Student’s <italic>t</italic>-test. Data in <bold>D</bold> were analysed by a two-way ANOVA with Sidak’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Conversion of <italic>P. aeruginosa</italic> whole cells to spheroplasts results in removal of the OM, and no OM contamination in the CM.</title><p>(<bold>A</bold>) Representative fluorescence microscopy images of <italic>P. aeruginosa</italic> PA14 cells labelled with fluorescein isothiocyanate (FITC, 0.5 mg ml<sup>−1</sup>) before (<italic>Whole Cells</italic>) and after (<italic>Spheroplasts</italic>) conversion to spheroplasts with EDTA (0.25 mg ml<sup>−1</sup>) and lysozyme (1 mg ml<sup>−1</sup>) in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose, as described in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (Scale bars: 5 μm). (<bold>B</bold>) Quantification of fluorescence from FITC-labelled <italic>P. aeruginosa</italic> PA14 cells before (<italic>Whole Cells</italic>) and after (<italic>Spheroplasts</italic>) conversion to spheroplasts (n = 3 in triplicate; *p&lt;0.05 compared to Whole Cells). Proteins in the OM of whole <italic>P. aeruginosa</italic> cells were tagged with a FITC fluorophore for 30 min, as previously described (<xref ref-type="bibr" rid="bib77">Wiegand et al., 2008</xref>). Following conversion of these labelled bacterial cells to spheroplasts, there was virtually no fluorescence from FITC visible by microscopy (<bold>A</bold>), or when quantifying the entire cell population (<bold>B</bold>). This confirmed that the OM had been successfully removed during the formation of spheroplasts, and that there was no contamination of the CM with material from the OM. Data in <bold>B</bold> were analysed by a paired Student’s <italic>t</italic>-test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Murepavadin increases the abundance of LPS in the cytoplasmic membrane (CM) of <italic>P. aeruginosa</italic>.</title><p>(<bold>A, B</bold>) Representative mass spectra (<bold>A</bold>) and quantification (<bold>B</bold>) showing the ratio of lipid A to a membrane phospholipid species (34:1,2) in the CM of <italic>P. aeruginosa</italic> PA14 spheroplasts exposed, or not, to murepavadin (0.05 µg ml<sup>−1</sup>) for 2 hr, as determined by MALDI-TOF-based lipidomics (n = 3 in duplicate). (<bold>C, D</bold>) Quantification of LPS levels in the OM (<bold>C</bold>) and CM (<bold>D</bold>) of <italic>P. aeruginosa</italic> PA14 during conversion to spheroplasts from whole cells pre-exposed, or not, to the LPS transport inhibitor murepavadin (0.05 μg ml<sup>−1</sup>) for 2 hr, as determined using the Limulus Amebocyte Lysate (LAL) assay (n = 3; ns: p&gt;0.05, *p&lt;0.05 compared to Untreated conditions). Exposure of <italic>P. aeruginosa</italic> to a sub-lethal concentration of the LPS transport inhibitor murepavadin triggered an accumulation of LPS in the CM, but had no effect on LPS levels in the OM. Furthermore, MALDI-TOF analysis confirmed that the LPS in murepavadin-treated cells was unmodified, confirming it could be accurately detected and quantified using the LAL assay. Data in <bold>B–D</bold> were analysed by a two-tailed paired Student’s <italic>t</italic>-test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>The LPS transport inhibitor murepavadin has no effect on reducing growth of <italic>P. aeruginosa</italic> at the concentration used.</title><p>Growth of <italic>P. aeruginosa</italic> PA14 cells in the presence of a sub-lethal concentration of the LptD inhibitor murepavadin at the indicated concentration, as determined by measuring OD<sub>600nm</sub> during 14 hr incubation at 37°C (n = 4; murepavadin-treated population not significantly different i.e. p&gt;0.05 compared to Untreated). Exposure of <italic>P. aeruginosa</italic> to murepavadin at the concentration used in experiments had no effect on blocking bacterial growth, confirming that this was a sub-lethal concentration. Data were analysed by a two-way ANOVA with Sidak’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Polymyxin B nonapeptide (PMBN) does not display synergy with murepavadin against <italic>P. aeruginosa</italic> PA14.</title><p>Checkerboard broth microdilution assay showing the growth-inhibitory interaction between PMBN and murepavadin against <italic>P. aeruginosa</italic> PA14 cells, as determined by measuring OD<sub>600nm</sub> after 18 hr incubation. In contrast to the synergistic interaction between colistin and murepavadin (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), there was no synergy observed between murepavadin and PMBN, with an FICI value of 1. The lack of synergy between PMBN and murepavadin confirms that the synergistic interaction between colistin and murepavadin was not due to colistin permeabilising the OM and enhancing the activity of murepavadin.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-figsupp5-v2.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>PMBN–murepavadin combination therapy does not promote killing of <italic>P. aeruginosa</italic>.</title><p>Survival of <italic>P. aeruginosa</italic> PA14 cells exposed to polymyxin B nonapeptide (1.67 µg ml<sup>−1</sup>) in the absence of presence of murepavadin (0.05 µg ml<sup>−1</sup>), as determined by c.f.u. counts (n = 4). In contrast to the marked increase in bacterial killing when colistin was used in combination with murepavadin (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), there was no decrease in survival of <italic>P. aeruginosa</italic> cells when treated with murepavadin alongside the molar equivalent concentration of PMBN (1.73 µM) as was used for colistin experiments in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (2 µg ml<sup>−1</sup>), although there was evidence of an additive effect. Since PMBN and colistin both share the ability to permeabilise the OM, this provided further confirmation that the enhanced bacterial killing was not due to colistin providing murepavadin with increased access to its target, but rather due to murepavadin-induced accumulation of LPS in the CM. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-figsupp6-v2.tif"/></fig><fig id="fig4s7" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 7.</label><caption><title>Murepavadin enhances the ability of colistin to damage the CM and trigger bacterial lysis.</title><p>(<bold>A</bold>) Permeabilisation of the CM of <italic>P. aeruginosa</italic> PA14 spheroplasts by colistin (2 µg ml<sup>−1</sup>) following exposure, or not, of bacteria to murepavadin (0.05 µg ml<sup>−1</sup>) for 2 hr prior to conversion to spheroplasts, as determined using 0.25 µM PI (n = 3; experiment performed on three independent occasions, *p&lt;0.01 for murepavadin pre-treated spheroplasts compared to untreated cells). (<bold>B</bold>) Lysis of <italic>P. aeruginosa</italic> PA14 spheroplasts by colistin (2 µg ml<sup>−1</sup>) following exposure, or not, of bacteria to murepavadin (0.05 µg ml<sup>−1</sup>) for 2 hr prior to conversion to spheroplasts, as measured by OD<sub>600nm</sub> readings (*p&lt;0.05 for murepavadin pre-treated spheroplasts compared to untreated cells). As observed with whole bacterial cells (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>), murepavadin-induced accumulation of LPS in the CM of <italic>P. aeruginosa</italic> spheroplasts significantly enhanced the ability of colistin to damage the CM (<bold>A</bold>). In keeping with this, the increased amount of LPS in the CM of murepavadin pre-treated spheroplasts led to an increase in colistin-mediated lysis (<bold>B</bold>). Crucially, these experiments were performed with cells that were pre-treated with murepavadin, with the LptD inhibitor washed out prior to exposure to colistin. This confirmed that it was murepavadin triggering LPS accumulation in the CM that led to an increase in bacterial lysis in response to colistin, rather than the polymyxin antibiotic enhancing murepavadin activity through OM permeabilisation. Data in <bold>A, B</bold> were analysed by a two-way ANOVA with Sidak’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig4-figsupp7-v2.tif"/></fig></fig-group><p>To confirm that sub-lethal concentrations of murepavadin altered LPS abundance in the CM, <italic>P. aeruginosa</italic> was incubated with murepavadin, before the amount of LPS in whole cells and spheroplasts was measured using the well-established Limulus Amoebocyte Lysate (LAL) assay, since previous work has shown this approach to be a highly accurate way of quantifying LPS in whole cell lysates (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>; <xref ref-type="bibr" rid="bib30">Hoppe Parr et al., 2017</xref>). The suitability of the LAL assay was further confirmed using a MALDI-TOF-based lipidomic analysis of spheroplast lysates, which confirmed that the LPS in both murepavadin-exposed and untreated bacteria was unmodified and thus able to be accurately detected and quantified (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>; <xref ref-type="bibr" rid="bib70">Takayama et al., 1984</xref>). Sub-lethal concentrations of murepavadin caused a slight reduction in LPS levels in the OM of <italic>P. aeruginosa</italic> cells, but a significant increase in the amount of LPS in the CM compared to untreated spheroplasts (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). Moreover, our lipidomic analysis revealed that the ratio of lipid A:phospholipid increased in <italic>P. aeruginosa</italic> spheroplasts pre-exposed to murepavadin, confirming that the LptD inhibitor caused LPS to accumulate in the CM (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><p>Next, we proceeded to test whether LPS accumulation in the CM increased the susceptibility of <italic>P. aeruginosa</italic> to colistin. We started by examining the effect of colistin on the OM and CM of <italic>P. aeruginosa</italic> exposed, or not, to murepavadin. Despite the slight reduction of LPS at the OM caused by murepavadin, colistin permeabilised the OM to the same extent as bacteria that had not been exposed to murepavadin, with similar levels of NPN uptake (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). By contrast, however, murepavadin significantly enhanced permeabilisation of the CM by colistin in whole cells of <italic>P. aeruginosa</italic>, as determined via uptake of PI (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Thus, an increase in LPS levels in the CM promoted colistin-mediated damage, in keeping with our conclusion that LPS in the CM is the target of the polymyxin antibiotic. Furthermore, <italic>P. aeruginosa</italic> cells exposed to murepavadin were more rapidly lysed by colistin than untreated cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><p>Taken together, these findings indicated that LPS accumulation in the CM increased susceptibility to the polymyxin antibiotic. However, an alternative explanation for the synergy between colistin and murepavadin was that polymyxin-mediated damage to the OM enabled murepavadin greater access to LptD in the periplasm. To test this, we first examined whether the OM permeabilising agent polymyxin B nonapeptide (PMBN) also synergised with murepavadin. However, we did not see synergy in MIC checkerboard or bactericidal assays between PMBN and murepavadin (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>, <xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>). Next, we pre-treated <italic>P. aeruginosa</italic> with murepavadin alone to cause LPS accumulation in the CM and then removed the murepavadin by washing before converting the whole cells to spheroplasts and exposing these to colistin alone. The murepavadin pre-treated spheroplasts were much more susceptible to colistin-induced CM damage and lysis than untreated spheroplasts (<xref ref-type="fig" rid="fig4s7">Figure 4—figure supplement 7</xref>). Therefore, colistin does not sensitise <italic>P. aeruginosa</italic> to murepavadin by compromising the OM; rather, murepavadin-induced accumulation of LPS in the CM potentiates the activity of colistin.</p><p>Taken together, these experiments provided further evidence that colistin targets LPS in the CM and suggest that murepavadin and colistin might form a useful combination therapy.</p></sec><sec id="s2-5"><title>Combination therapy with colistin and murepavadin promotes clearance of <italic>P. aeruginosa</italic></title><p><italic>P. aeruginosa</italic> is a major cause of chronic lung infection in people with cystic fibrosis (CF) and bronchiectasis. In both conditions, disease severity can rapidly increase during episodes of ‘exacerbation’ which must be treated aggressively to quickly restore lung function and reduce long-term damage (<xref ref-type="bibr" rid="bib61">Polverino et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Karampitsakos et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Stanford et al., 2021</xref>). Therefore, having shown that murepavadin sensitised the CM to colistin-mediated damage, we wanted to determine whether this translated into enhanced antibacterial activity against relevant clinical isolates and increased treatment efficacy in vivo. We found that a sub-lethal concentration of murepavadin sensitised <italic>P. aeruginosa</italic> PA14 to a normally sub-lethal concentration of colistin (2 µg ml<sup>−1</sup>), resulting in &gt;10,000-fold reduction in c.f.u. counts relative to bacteria incubated with murepavadin or colistin alone after 8 hr (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We also found that murepavadin potentiated the activity of even lower concentrations of colistin (1 µg ml<sup>−1</sup>), with exposure to the LPS transport inhibitor increasing the ability of the polymyxin antibiotic to damage the CM, triggering bacterial lysis and cell death (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Colistin-murepavadin combination therapy promotes killing of <italic>P. aeruginosa</italic> in vitro and in vivo.</title><p>(<bold>A</bold>) Survival of <italic>P. aeruginosa</italic> PA14 cells exposed to colistin (2 µg ml<sup>−1</sup>) in the absence of presence of murepavadin (0.05 µg ml<sup>−1</sup>), as determined by c.f.u. counts (n = 4; *p&lt;0.05 for colistin and murepavadin-exposed cells compared to colistin alone). (<bold>B</bold>) Survival or growth of a panel of clinical multidrug-resistant <italic>P. aeruginosa</italic> strains isolated from the sputum of cystic fibrosis patients after 8 hr exposure to colistin (2 µg ml<sup>−1</sup>) alone, or in the presence of a sub-lethal concentration (0.5× MIC) of murepavadin, as determined by c.f.u. counts (n = 4; *p&lt;0.01 for colistin and murepavadin-exposed cells compared to colistin alone). (<bold>C</bold>) Burden of <italic>P. aeruginosa</italic> PA14 in the lungs of mice after 3 hr treatment with murepavadin (0.25 mg kg<sup>-1</sup>), colistin (5 mg kg<sup>-1</sup>), neither antibiotic, or both antibiotics in combination, as determined by c.f.u. counts (each data point represents a single mouse; for each group, n = 5; ns: p&gt;0.05, *p&lt;0.001 compared to untreated mice). Data in (<bold>A, B</bold>) were analysed by a two-way ANOVA with Dunnett’s (<bold>A</bold>) or Sidak’s (<bold>B</bold>) post hoc tests. Data in (<bold>C</bold>) were analysed by a Kruskal–Wallis test with Dunn’s post hoc test. Data are presented as the arithmetic mean, and error bars, where shown, represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Murepavadin potentiates the activity of sub-lethal colistin concentrations, leading to enhanced CM damage, cell lysis and bacterial killing.</title><p>(<bold>A</bold>) OM disruption of <italic>P. aeruginosa</italic> PA14 cells during 10 min exposure to colistin (1 μg ml<sup>−1</sup>) in the absence or presence of murepavadin (0.05 μg ml<sup>−1</sup>), as assessed by uptake of the fluorescent dye NPN (10 μM) (n = 4, each data point represents the arithmetic mean of 20 replicate measurements; ns: p&gt;0.05 between colistin-treated bacteria). (<bold>B</bold>) CM disruption of <italic>P. aeruginosa</italic> PA14 cells exposed to colistin (1 μg ml<sup>−1</sup>) in the absence or presence of murepavadin (0.05 μg ml<sup>−1</sup>), as determined using 2.5 μM PI (n = 4; *p&lt;0.0001 for murepavadin-exposed cells compared to Colistin alone). (<bold>C</bold>) Growth of <italic>P. aeruginosa</italic> PA14 cells exposed to colistin (1 μg ml<sup>−1</sup>) in the absence or presence of murepavadin (0.05 μg ml<sup>−1</sup>), as measured by OD<sub>595nm</sub> readings (n = 4; *p&lt;0.01 for murepavadin-exposed cells compared to Colistin alone). (<bold>D</bold>) Survival of <italic>P. aeruginosa</italic> PA14 cells exposed to colistin (1 μg ml<sup>−1</sup>) in the absence or presence of murepavadin (0.05 μg ml<sup>−1</sup>), as determined by c.f.u. counts (n = 4; *p&lt;0.0001 for murepavadin-exposed cells compared to Colistin alone). Exposure of <italic>P. aeruginosa</italic> to murepavadin, which leads to accumulation of LPS in the CM, had no impact on the ability of colistin to damage the OM, further confirming that the LPS transport inhibitor, at the concentration used, did not significantly affect LPS levels in the OM (<bold>A</bold>). However, a normally sub-lethal concentration of colistin was able to permeabilise the CM of murepavadin-exposed whole cells of <italic>P. aeruginosa</italic> (<bold>B</bold>). This enhanced CM disruption by a sub-lethal concentration of colistin in combination with murepavadin led to an increase in lysis of <italic>P. aeruginosa</italic> cells, and ultimately greater bacterial killing (<bold>C, D</bold>). Together, these data showed that accumulation of LPS in the CM via murepavadin enhanced the bactericidal activity of colistin, even at concentrations of the polymyxin antibiotic that otherwise had no growth inhibitory effects. Data in <bold>A</bold> were analysed by a one-way ANOVA with Tukey’s post hoc test. Data in <bold>B, C</bold> were analysed by a two-way ANOVA with Dunnett’s post hoc test. Data in <bold>D</bold> were analysed by a two-way ANOVA with Tukey’s post hoc test. Data are presented as the arithmetic mean, and error bars represent the standard deviation of the mean.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Antibiogram summarising the antimicrobial susceptibilities of a panel of MDR <italic>P. aeruginosa</italic> human clinical strains isolated from sputum samples of cystic fibrosis patients.</title><p>S: susceptible (green), I: intermediate (orange), R: resistant (red). Bacterial strains were isolated and antimicrobial susceptibility testing was performed at the Royal Brompton Hospital, Royal Brompton, and Harefield NHS Foundation Trust.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig5-figsupp2-v2.tif"/></fig></fig-group><p>We next examined a panel of 15 multi-drug resistant <italic>P. aeruginosa</italic> clinical strains, isolated from the sputum of CF patients, to investigate whether murepavadin increased colistin-mediated bacterial killing (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Of these 15 clinical isolates, 14 were susceptible to murepavadin alone, whilst one strain was resistant to the LptD inhibitor (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In 11 out of 14 murepavadin-susceptible CF isolates tested (79%), sub-lethal concentrations of murepavadin caused a significant increase in the bactericidal activity of colistin against <italic>P. aeruginosa</italic> (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Importantly, murepavadin did not affect the bactericidal activity of colistin against the strain that was resistant to the LptD inhibitor (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This confirmed that the potentiating effects of the LptD inhibitor on polymyxin-mediated killing were not due to off-target effects.</p><p>Next, we employed a high inoculum <italic>P. aeruginosa</italic> murine lung infection model and used a short treatment duration to assess how quickly combined colistin and murepavadin therapy could reduce bacterial burden, relative to mono-therapy. Mice were inoculated via the intranasal route with <italic>P. aeruginosa</italic> PA14 to cause a lung infection, and then treated intranasally with PBS alone, or PBS containing colistin only (5 mg kg<sup>−1</sup>), murepavadin only (0.25 mg kg<sup>−1</sup>), or colistin and murepavadin combined at the concentrations used for mono-treatment. These concentrations were based on those used previously to mimic treatment of human lung infections, and the route of delivery is similar to that used clinically (<xref ref-type="bibr" rid="bib7">Bernardini et al., 2019</xref>; <xref ref-type="bibr" rid="bib79">Yapa et al., 2014</xref>; <xref ref-type="bibr" rid="bib49">Melchers et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Aoki et al., 2009</xref>). Mono-therapy with colistin alone or murepavadin alone had very little effect on the bacterial load assessed after 3 hr treatment compared with the no-treatment control (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). By contrast, combination therapy with colistin and murepavadin caused a ~500-fold reduction in c.f.u. counts relative to the no-treatment control (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Therefore, murepavadin synergises with colistin both in vitro and in vivo, suggesting it may be useful as a combination therapeutic approach for lung infections caused by <italic>P. aeruginosa</italic>.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Colistin is an increasingly important last-resort antibiotic used to treat infections caused by multi-drug-resistant Gram-negative pathogens, including <italic>P. aeruginosa</italic>, <italic>K. pneumoniae</italic>, and <italic>E. coli</italic> (<xref ref-type="bibr" rid="bib27">Garg et al., 2017</xref>; <xref ref-type="bibr" rid="bib9">Biswas et al., 2012</xref>; <xref ref-type="bibr" rid="bib71">Thomas et al., 2019</xref>). However, treatment failure occurs frequently, and resistance is a growing concern (<xref ref-type="bibr" rid="bib23">Falagas et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Paul et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Linden et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Tran et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Satlin et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">MacNair et al., 2018</xref>). Efforts to address these issues are compromised by a poor understanding of colistin’s bactericidal mode of action. Whilst the initial interactions of colistin with LPS in the OM of Gram-negative bacteria were well established, it was unclear how the antibiotic traversed the OM and damaged the CM to cause cell lysis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In this work, we demonstrate that colistin targets LPS in the CM, resulting in membrane permeabilisation, bacterial lysis, and killing (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Colistin kills bacteria by targeting LPS in both the outer and cytoplasmic membrane (CM), leading to disruption of the cell envelope and bacterial lysis.</title><p>Diagrammatic representation of the novel proposed mechanism of action of colistin: Colistin binds to LPS in the OM (1), displacing cations that form bridges between LPS molecules, which leads to destabilisation of the OM (2). As a consequence of the weakening of intermolecular bonds in the LPS monolayer, LPS is released from the bacterial surface (3), allowing colistin to further damage the OM via the action of the polymyxin lipid tail (4). This provides colistin with access to the periplasm, where colistin interacts with LPS in the CM (5) that is awaiting transport to the OM by the LptABCDEFG machinery after being synthesised in the cytoplasm and flipped to the outer leaflet of the CM by MsbA. As in the OM, colistin binding to LPS results in displacement of cation bridges and disruption of the CM (6), which it ultimately permeabilises (7), culminating in the loss of cytoplasmic contents, cell lysis, and bacterial death (8).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65836-fig6-v2.tif"/></fig><p>Our conclusion that colistin targets LPS in the CM was based initially on experiments with <italic>E. coli</italic> expressing the <italic>mcr</italic>-1 colistin resistance determinant. MCR-1 modifies lipid A with a pEtN moiety as it passes through the CM on its way to the OM (<xref ref-type="bibr" rid="bib44">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Nang et al., 2019</xref>). Since MCR-1 specifically protected spheroplasts from colistin but not nisin or daptomycin, which both target phospholipid bilayers, it was clear that colistin did not share the same target as the other two CAMPs. Given the only difference between <italic>E. coli</italic> spheroplasts expressing <italic>mcr</italic>-1 and pEmpty spheroplasts was modified LPS, our data reveal that colistin targets LPS in the CM, leading to disruption of the CM, which is a pre-requisite for subsequent cell lysis and bacterial killing (<xref ref-type="bibr" rid="bib2">Allison and Lambert, 2015</xref>). These findings were then supported by experiments showing that LPS accumulation in the CM of <italic>P. aeruginosa</italic> sensitised this bacterium to colistin.</p><p>Similar to <italic>Salmonella</italic> and <italic>E. coli</italic>, the abundance of LPS in the CM of <italic>P. aeruginosa</italic> was found to be ~100 times lower than the OM, indicating that only about 1% of total LPS is present in the CM (<xref ref-type="bibr" rid="bib80">Zendo et al., 2010</xref>; <xref ref-type="bibr" rid="bib57">Osborn et al., 1972</xref>). However, studies with model membranes have shown that the presence of low concentrations of LPS (1% total composition) in phospholipid bilayer membranes was both necessary and sufficient for colistin-mediated permeabilisation (<xref ref-type="bibr" rid="bib35">Khadka et al., 2018</xref>). Therefore, our conclusion explains how an antibiotic with a high degree of specificity for LPS could damage both the OM and CM (<xref ref-type="bibr" rid="bib74">Velkov et al., 2010</xref>). The reason why MCR-1 protected the CM but not OM from colistin-mediated damage is most likely due to the lower proportion of unmodified LPS at the CM (21 ± 2%) relative to the OM (42 ± 19%) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Furthermore, the overall abundance of LPS in the CM is very low, resulting in very few targets (i.e. unmodified LPS molecules) for colistin in the CM of <italic>mcr-1</italic>-expressing <italic>E. coli</italic>. By contrast, the OM of MCR-1-producing <italic>E. coli</italic> contains many more unmodified LPS molecules that can be bound by colistin, explaining why colistin is able to damage this structure, but cannot permeabilise the CM of <italic>E. coli</italic> expressing <italic>mcr-1</italic> at a physiologically relevant concentration (<xref ref-type="bibr" rid="bib35">Khadka et al., 2018</xref>). Whether colistin resistance conferred by chromosomal mutations in two-component systems is also mediated by modified LPS in the CM remains to be tested (<xref ref-type="bibr" rid="bib13">Carroll et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Nang et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Skov and Monnet, 2016</xref>; <xref ref-type="bibr" rid="bib75">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Raetz et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Simpson and Trent, 2019</xref>).</p><p>Our data showing that colistin requires unmodified LPS to be present in the CM to kill bacteria explains how an antibiotic with high affinity and specificity for LPS causes disruption to both the OM and CM (<xref ref-type="bibr" rid="bib74">Velkov et al., 2010</xref>). Furthermore, these findings provide support for the observations that colistin does not damage the OM of colistin-resistant <italic>A. baumannii</italic> isolates where LPS has been replaced by a phospholipid bilayer, and that polymyxins cause only minimal disruption to model phospholipid membranes unless LPS is present (<xref ref-type="bibr" rid="bib35">Khadka et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Moffatt et al., 2010</xref>; <xref ref-type="bibr" rid="bib81">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Fu et al., 2020</xref>).</p><p>Whilst the interaction of colistin with LPS in the CM is likely to share similarities with the same process at the OM, there are also likely to be differences owing to the differing concentrations of LPS between the two membranes (<xref ref-type="bibr" rid="bib35">Khadka et al., 2018</xref>; <xref ref-type="bibr" rid="bib80">Zendo et al., 2010</xref>; <xref ref-type="bibr" rid="bib57">Osborn et al., 1972</xref>). In the OM, LPS is a highly abundant component with molecules tightly packed and stabilised with cation bridges. By contrast, LPS is a minority component in the CM, which may affect the rate and degree to which the CM is disrupted by polymyxins. In support of this, whilst colistin induced OM damage within minutes of bacterial exposure to the antibiotic, disruption of the CM took much longer. Even when spheroplasts lacking an OM were exposed to colistin, it still took more than 2 hr for CM permeabilisation to occur. Therefore, it appears that colistin-mediated disruption of the CM is considerably less efficient than that of the OM, likely due to the much lower levels of LPS present in the CM.</p><p>In addition to disruption of both the OM and IM, it has been proposed that the lethal activity of polymyxin antibiotics may be due, at least in part, to: disruption of NADH-quinone reductase; the generation of reactive oxygen species (ROS); the binding of the antibiotic to ribosomes; and the fusion of the OM and CM, leading to phospholipid exchange (<xref ref-type="bibr" rid="bib12">Cajal et al., 1996</xref>; <xref ref-type="bibr" rid="bib17">Clausell et al., 2006</xref>; <xref ref-type="bibr" rid="bib18">Clausell et al., 2007</xref>; <xref ref-type="bibr" rid="bib20">Deris et al., 2014</xref>; <xref ref-type="bibr" rid="bib1">Ajiboye et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Li and Velkov, 2019</xref>; <xref ref-type="bibr" rid="bib5">Ayoub Moubareck, 2020</xref>; <xref ref-type="bibr" rid="bib22">El-Sayed Ahmed et al., 2020</xref>). However, whilst these have been considered as discrete events or alternative mechanisms of action, it is possible that all these phenomena occur as downstream consequences of colistin-mediated CM disruption. For example, NADH-quinone reductase is a component of the electronic transport chain (ETC), which is located within the CM and may therefore be disrupted by membrane damage, whilst the generation of ROS may arise via disruption of the ETC as has been proposed for the CAMP LL-37 (<xref ref-type="bibr" rid="bib20">Deris et al., 2014</xref>; <xref ref-type="bibr" rid="bib5">Ayoub Moubareck, 2020</xref>; <xref ref-type="bibr" rid="bib14">Choi et al., 2017</xref>). The fusion of the OM and CM and subsequent exchange of lipids appears to depend upon the interaction of the polymyxin with, and presumably disruption of, both membranes (<xref ref-type="bibr" rid="bib12">Cajal et al., 1996</xref>; <xref ref-type="bibr" rid="bib17">Clausell et al., 2006</xref>; <xref ref-type="bibr" rid="bib18">Clausell et al., 2007</xref>; <xref ref-type="bibr" rid="bib5">Ayoub Moubareck, 2020</xref>; <xref ref-type="bibr" rid="bib22">El-Sayed Ahmed et al., 2020</xref>). Finally, the interaction of polymyxins with ribosomes requires the antibiotic to pass through the CM to access the cytoplasm (<xref ref-type="bibr" rid="bib48">McCoy et al., 2013</xref>). Therefore, whilst the disruption of the CM by polymyxin antibiotics is the key step required for bacterial killing, this may be due to multiple deleterious effects on cellular processes.</p><p>Our findings provide strong evidence that colistin targets LPS in the CM, in addition to the OM, and that this is required for the bactericidal and lytic activity of the antibiotic at clinically relevant concentrations. This insight into the mode of action of colistin enabled us to devise a new therapeutic approach to enhance colistin efficacy. Using the LptD inhibitor murepavadin, which is in development as an inhaled treatment for <italic>P. aeruginosa</italic> infections, we triggered LPS accumulation in the CM, and thereby increased the susceptibility of bacteria to colistin (<xref ref-type="bibr" rid="bib40">Lehman and Grabowicz, 2019</xref>). The potential clinical utility of this approach was demonstrated by showing enhanced activity of colistin–murepavadin combination therapy against a panel of clinical CF isolates, as well as potent efficacy in a murine model of <italic>P. aeruginosa</italic> lung infection. It is anticipated that a combination of colistin and murepavadin could enhance the low treatment efficacy of polymyxin antibiotics and may also limit the toxic side effects associated with both compounds by enabling the use of lower doses of the drugs (<xref ref-type="bibr" rid="bib40">Lehman and Grabowicz, 2019</xref>).</p><p>Interestingly, whilst we found that blocking LPS transport to the OM sensitised bacteria to colistin, previous work has shown that novobiocin increases the susceptibility of bacteria to colistin by increasing LPS transport to the OM (<xref ref-type="bibr" rid="bib47">Mandler et al., 2018</xref>). This might suggest that novobiocin reduces LPS levels in the CM and thus contradicts our findings. However, transport of LPS to the OM is regulated such that this process does not deplete LPS in the CM (<xref ref-type="bibr" rid="bib78">Xie et al., 2018</xref>). Furthermore, LPS biosynthesis is tightly regulated at the CM in response to the abundance of LPS by PbgA, LapB, and FtsH (<xref ref-type="bibr" rid="bib15">Clairfeuille et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Guest et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Fivenson and Bernhardt, 2020</xref>; <xref ref-type="bibr" rid="bib54">O'Rourke et al., 2020</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2006</xref>). Therefore, it is expected that LPS synthesis would be increased to address the elevated rate of transport to the OM, which might lead to elevated levels of LPS in the CM as it is produced to meet demand. In support of this, novobiocin exposure increases the expression of <italic>lpxC</italic> in <italic>E. coli</italic>, which encodes the enzyme that is the first committed step in LPS biosynthesis and provides a key checkpoint in LPS production (<xref ref-type="bibr" rid="bib63">Raetz et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Simpson and Trent, 2019</xref>; <xref ref-type="bibr" rid="bib54">O'Rourke et al., 2020</xref>). However, the effect of novobiocin on LPS abundance in the CM remains to be tested.</p><p>It should be noted that whilst bacteria can modulate LPS biosynthesis to maintain LPS abundance in the CM, there is no mechanism to remove LPS from the CM, which is why LPS accumulation occurs with murepavadin.</p><p>In summary, this work contributes to our understanding of the mechanism of action of colistin by demonstrating that polymyxin antibiotics target LPS in both the OM and the CM, and that this leads to the disruption of both membranes, resulting in the bactericidal and lytic activities of the antibiotic. Modulation of LPS levels in the CM can enhance colistin activity, providing the foundations for new approaches to enhance the efficacy of this antibiotic of last resort.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td>MC1000</td><td><xref ref-type="bibr" rid="bib21">Dortet et al., 2018</xref> PMID:<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/30442963">30442963</ext-link></td><td>pEmpty</td><td>Background strain (<italic>araD139</italic>, ∆(ara, leu)7697, ∆<italic>lacX74</italic>, <italic>galU, galK, strA</italic>) harbouring the IPTG-inducible pDM1 plasmid (GenBank MN128719)</td></tr><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td>MC1000</td><td><xref ref-type="bibr" rid="bib21">Dortet et al., 2018</xref> PMID:<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/30442963">30442963</ext-link></td><td><italic>mcr-</italic>1</td><td>MC1000 strain harbouring the pDM1 plasmid encoding the <italic>mcr-1</italic> gene amplified from a clinical <italic>E. coli</italic> isolate</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>PA14</td><td><xref ref-type="bibr" rid="bib38">Lee et al., 2006</xref> PMID:<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17038190">17038190</ext-link></td><td>PA14</td><td>Wild-type reference strain; highly virulent human isolate representing most common clonal group worldwide</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK3</td><td>This study</td><td>AK3</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient – mucoid strain</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK10</td><td>This study</td><td>AK10</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK20</td><td>This study</td><td>AK20</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK6</td><td>This study</td><td>AK6</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient – mucoid strain</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK12</td><td>This study</td><td>AK12</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient – mucoid strain</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK8</td><td>This study</td><td>AK8</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient – mucoid strain</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK17</td><td>This study</td><td>AK17</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK9</td><td>This study</td><td>AK9</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK14</td><td>This study</td><td>AK14</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK5</td><td>This study</td><td>AK5</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient – mucoid strain</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK11</td><td>This study</td><td>AK11</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient – mucoid strain</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK13</td><td>This study</td><td>AK13</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK18</td><td>This study</td><td>AK18</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK22</td><td>This study</td><td>AK22</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient</td></tr><tr><td>Strain, strain background (<italic>Pseudomonas aeruginosa</italic>)</td><td>AK19</td><td>This study</td><td>AK19</td><td>Multi-drug resistant human clinical isolate from sputum of cystic fibrosis patient – murepavadin-resistant</td></tr><tr><td>Chemical compound, drug</td><td>Colistin</td><td>Sigma-Aldrich</td><td>C4461-1G</td><td>Targets LPS</td></tr><tr><td>Chemical compound, drug</td><td>Murepavadin (POL7080)</td><td>DC Chemicals</td><td>DC11273</td><td>Targets LptD</td></tr><tr><td>Chemical compound, drug</td><td>Daptomycin</td><td>Bio-Techne Ltd</td><td>3917/10</td><td>Targets phosphatidylglycerol in the bacterial membrane</td></tr><tr><td>Chemical compound, drug</td><td>Nisin</td><td>Sigma-Aldrich</td><td>N5764-5G</td><td>Targets bacterial membranes</td></tr><tr><td>Chemical compound, drug</td><td>Rifampicin</td><td>Molekula Ltd</td><td>32609202</td><td>Targets RNA Polymerase</td></tr><tr><td>Chemical compound, drug</td><td>Polymyxin B nonapeptide (PMBN)</td><td>Sigma-Aldrich</td><td>P2076-5MG</td><td>Permeabilises the OM</td></tr><tr><td>Chemical compound, drug</td><td>Tetracycline</td><td>Sigma-Aldrich</td><td>87128–25G</td><td>Protein synthesis inhibitor</td></tr><tr><td>Commercial assay or kit</td><td>LAL Chromogenic Endotoxin Quantitation Kit</td><td>Thermo Scientific Pierce</td><td>88282</td><td>Quantitative assay for LPS</td></tr><tr><td>Chemical compound, drug</td><td>Isopropyl β-d-1-thiogalactopyranoside (IPTG)</td><td>Melford Laboratories</td><td>MB1008</td><td>Induces gene expression</td></tr><tr><td>Chemical compound, drug</td><td>Lysozyme from chicken egg white</td><td>Sigma-Aldrich</td><td>L6876-1G</td><td>Degrades peptidoglycan</td></tr><tr><td>Chemical compound, drug</td><td>Ethylenediaminetetraacetic acid (EDTA)</td><td>Sigma-Aldrich</td><td>E6511-100G</td><td>Removes OM from bacteria</td></tr><tr><td>Chemical compound, drug</td><td>Trypsin</td><td>Sigma-Aldrich</td><td>T7309-1G</td><td>Degrades proteins</td></tr><tr><td>Chemical compound, drug</td><td>Propidium iodide (PI)</td><td>Sigma-Aldrich</td><td>P4864-10ML</td><td>Fluoresces when bound to DNA</td></tr><tr><td>Chemical compound, drug</td><td>Fluorescein 5 (6)-isothiocyanate</td><td>Sigma-Aldrich</td><td>46950–50MG-F</td><td>Used to label proteins with a fluorescent tag</td></tr><tr><td>Chemical compound, drug</td><td><italic>N</italic>-phenyl-1-napthylamine (NPN)</td><td>Acros Organics</td><td>147160250</td><td>Fluoresces when bound to phospholipids</td></tr><tr><td>Chemical compound, drug</td><td>FITC-labelled Poly-L-lysine (PLL)</td><td>Sigma-Aldrich</td><td>P3543-10MG</td><td>Used to measure membrane surface charge</td></tr><tr><td>Chemical compound, drug</td><td>6-Dodecanoyl-N,N-dimethyl-2-naphthylamine (Laurdan)</td><td>Sigma-Aldrich</td><td>40227–100 MG</td><td>Used to measure membrane fluidity</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Bacterial strains and growth conditions</title><p>The bacterial strains used in this study are listed in Key resources table. For each experiment, all strains were grown in Luria broth (LB; Thermo Fisher Scientific, USA) for 18 hr to stationary phase at 37°C with shaking (180 r.p.m.). For routine culture of bacteria on solid media, strains were grown on LB supplemented with 1.5% technical agar (BD Biosciences, USA). Liquid and solid growth media were supplemented with tetracycline (12.5 μg ml<sup>−1</sup>; Sigma-Aldrich, USA) and isopropyl-β-D-thiogalactoside (IPTG, Melford Laboratories, UK; used at 0.5 mM unless stated otherwise) where required. Enumeration of bacterial c.f.u. was done by plating 10-fold serial dilutions of bacterial cultures on to Mueller-Hinton agar (MHA; Thermo Fisher Scientific) plates. Inoculated agar plates were incubated statically for 18 hr in air at 37°C.</p></sec><sec id="s4-2"><title>Determination of MICs of antibiotics</title><p>The MIC of colistin and murepavadin against bacterial strains was determined by the broth microdilution protocol (<xref ref-type="bibr" rid="bib77">Wiegand et al., 2008</xref>). A microtitre plate was used to prepare a range of antibiotic concentrations in 200 μl cation-adjusted Mueller-Hinton broth (CA-MHB; Thermo Fisher Scientific) by two-fold serial dilutions. For certain experiments, checkerboard analyses were performed by preparing two-fold serial dilutions of two antibiotics in different directions, generating an 8 × 8 matrix to assess the MICs of the relevant antibiotics in combination, with FICI values calculated as previously described (<xref ref-type="bibr" rid="bib55">Odds, 2003</xref>). Stationary-phase bacteria were diluted 1000-fold in fresh CA-MHB and seeded into each well of the microtitre plate to a final concentration of 5 × 10<sup>5</sup> c.f.u. ml<sup>−1</sup>. The microtitre plates were then incubated statically at 37°C for 18 hr in air, after which point the MIC was defined as the lowest antibiotic concentration at which there was no visible growth of bacteria. In some cases, the extent of bacterial growth after 18 hr incubation was also determined by obtaining OD<sub>595nm</sub> measurements using a Bio-Rad iMark microplate absorbance reader (Bio-Rad Laboratories, USA).</p></sec><sec id="s4-3"><title>Bacterial growth assay</title><p>Stationary-phase bacteria were diluted 1000-fold in fresh CA-MHB, and 4 μl was seeded into the wells of a microtitre plate containing 200 μl CA-MHB, and for some experiments the LptD inhibitor murepavadin, to give a final inoculum of 5 × 10<sup>5</sup> c.f.u. ml<sup>−1</sup>. The microtitre plate was incubated with shaking (180 r.p.m.) at 37°C for 16 hr in a Tecan Infinite 200 Pro multiwell plate reader (Tecan Group Ltd., Switzerland) and optical density measurements were taken at 600 nm every 15 min.</p></sec><sec id="s4-4"><title>Production of spheroplasts</title><p>Spheroplasts of <italic>E. coli</italic> and <italic>P. aeruginosa</italic> strains lacking an OM and cell wall were generated as previously described (<xref ref-type="bibr" rid="bib76">Weiss and Fraser, 1973</xref>). Briefly, stationary-phase bacteria grown overnight were washed twice by centrifugation (12,300 × <italic>g</italic>, 3 min) followed by resuspension in CA-MHB, and added at a final inoculum of 10<sup>8</sup> c.f.u. ml<sup>−1</sup> to 9 ml CA-MHB containing for some experiments varying concentration of IPTG, or the LPS transport inhibitor murepavadin. Cultures were then incubated at 37°C with shaking (180 r.p.m.) for 2 hr. After the incubation, bacteria were washed twice by centrifuging (3273 × <italic>g</italic>, 20 min, 4°C) and resuspending first in 10 ml Tris buffer (0.03 M, pH 8.0; Sigma-Aldrich), and subsequently in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose. EDTA (250 µl, 10 mg ml<sup>−1</sup>; Sigma-Aldrich) and lysozyme (1 ml, 10 mg ml<sup>−1</sup>; Roche, Switzerland) were added to remove the OM and cell wall respectively, and the cell suspension was incubated for 1 hr in a water bath shaker at 30°C. Trypsin (500 µl, 10 mg ml<sup>−1</sup>; Sigma-Aldrich) was then added, and the culture again incubated at 30°C in a water bath shaker for 15 min. The resulting spheroplasts produced were harvested by mild centrifugation (2000 × <italic>g</italic>, 20 min, 4°C), with the supernatant containing the removed OM extracted for further analysis. Successful conversion of bacterial whole cells into spheroplasts was confirmed using phase-contrast microscopy, as detailed below.</p></sec><sec id="s4-5"><title>Confirmation of successful spheroplast formation</title><p>Whole cells of <italic>E. coli</italic> and <italic>P. aeruginosa</italic> grown overnight were washed twice by centrifugation (12,300 × <italic>g</italic>, 3 min) and resuspension in CA-MHB, added at a final inoculum of 10<sup>8</sup> c.f.u. ml<sup>−1</sup> to 9 ml CA-MHB, and incubated for 2 hr at 37°C with shaking (180 r.p.m.). OM proteins of these bacteria were subsequently labelled with fluorescein isothiocyanate (FITC, Sigma-Aldrich) as previously described (<xref ref-type="bibr" rid="bib45">Loh and Ward, 2012</xref>). Bacterial cells were washed twice by centrifugation (3273 × <italic>g</italic>, 20 min, 4°C) and resuspension in 10 ml Labelling Buffer (50 mM Na<sub>2</sub>CO<sub>3</sub>, 100 mM NaCl, pH 8.0), to which FITC was added at a final concentration of 0.5 mg ml<sup>−1</sup>. Bacteria were incubated for 30 min at room temperature, before labelled cells were harvested by centrifuging (3273 × <italic>g</italic>, 20 min, 4°C) and washed thrice by resuspending in 10 ml Tris buffer (0.03 M, pH 8.0) containing 20% sucrose. 1 ml of FITC-labelled bacteria was extracted and centrifuged (12,300 × <italic>g</italic>, 3 min), and the cells were fixed in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS). The remaining 9 ml of FITC-labelled cells were converted into spheroplasts, as described above. The spheroplasts produced were recovered by mild centrifugation (2000 × <italic>g</italic>, 20 min, 4°C) and resuspension in 9 ml Tris buffer (0.03 M, pH 8.0) containing 20% sucrose, before 1 ml of spheroplasts were fixed in the same way as with whole cells. The amount of FITC fluorescence in the OM of whole cells and CM of spheroplasts was observed using fluorescence microscopy, as described below. For quantification of FITC fluorescence, 200 µl samples of the fixed bacterial suspensions were seeded into the wells of a black-walled microtitre plate, and fluorescence measured with a Tecan Infinite 200 Pro multiwell plate reader, using an excitation wavelength of 490 nm and an emission wavelength of 525 nm.</p></sec><sec id="s4-6"><title>Microscopy</title><p>For phase-contrast and fluorescence microscopy, a 5 µl sample of fixed bacterial whole cells or spheroplasts was spotted onto a thin 1.2% agarose gel patch prepared in distilled water on a microscope slide. Bacteria were imaged using an Axio Imager.A2 Zeiss microscope (Carl Zeiss Microscopy GmbH, Germany) at 1000× magnification with an oil immersion objective lens. The ZEN 2012 software was used for image acquisition, whilst analysis of cell length:width ratios was done using the FIJI/ImageJ software by measuring two perpendicular lines drawn through the centre of bacteria. For each experiment, all microscopy images were acquired and processed using identical settings throughout.</p></sec><sec id="s4-7"><title>Determination of LPS concentration and modification by mass spectroscopy</title><p>Spheroplasts from bacterial cells were prepared as described above and then resuspended in ddH<sub>2</sub>O (200 μl), before mild acid hydrolysis was performed via the addition of 2% (vol/vol) acetic acid in ddH<sub>2</sub>O (200 μl) and incubation at 100°C for 30 min. For experiments with whole cells, bacteria grown overnight to stationary-phase were washed three times by centrifuging and resuspending in ddH<sub>2</sub>O, and a mild acid hydrolysis was performed on these whole cells as described for spheroplasts. Acid-treated whole cells or spheroplasts were recovered by centrifugation (17,000 × <italic>g</italic>, 2 min), and the resulting pellet was washed before being resuspended in 50 μl ultrapure water. The whole cell or spheroplast suspension (0.5 μl) was then loaded immediately onto the target and overlaid with 1.2 μl of a matrix consisting of 9H-Pyrido[3,4-B]indole (Norharmane) (Sigma-Aldrich) dissolved in 90:10 (vol/vol) chloroform/methanol to a final concentration of 10 mg ml<sup>−1</sup>. The bacterial suspension and matrix were then mixed on the target before gentle drying under air at room temperature. MALDI-TOF mass spectroscopy analysis was undertaken with a MALDI Biotyper Sirius system (Bruker Daltonics, USA), using the linear negative-ion mode as described previously (<xref ref-type="bibr" rid="bib26">Furniss et al., 2019</xref>). Manual peak picking at masses relevant to phospholipids or lipid A was performed on the mass spectra obtained, and the corresponding signal intensities at the defined masses were determined. Peaks were considered only if their signal/noise ratio was at least 5. To determine the ratio of modified lipid A to unmodified lipid A, the area under the pETN-modified lipid A peak (<italic>m/z</italic> 1,919.2) was divided by the area under the peak corresponding to native lipid A (<italic>m/z</italic> 1,796.2). To determine the relative abundance of LPS, the sum of the area under the lipid A peaks (<italic>m/z</italic> 1447–1700) was divided by the sum of the area under representative phospholipid peaks (phospholipid 34:1,2, <italic>m/z</italic> 717–747). All mass spectra were generated and analysed with three biological replicates and two technical replicates.</p></sec><sec id="s4-8"><title>OM disruption assay</title><p>To detect damage to the OM of bacteria, the well-established NPN uptake assay was used (<xref ref-type="bibr" rid="bib29">Helander and Mattila-Sandholm, 2000</xref>). Stationary-phase bacterial cells were washed in fresh CA-MHB and diluted to an optical density (OD<sub>600nm</sub>) of 0.5 in 5 mM pH 7.2 HEPES buffer (Sigma-Aldrich). This bacterial suspension was added to wells containing the relevant antibiotics in HEPES buffer, as well as the fluorescent probe <italic>N</italic>-phenyl-1-naphthylamine (NPN; Acros Organics, USA) at a final concentration of 10 μM. Samples were placed in a black microtitre plate with clear-bottomed wells and fluorescence measured immediately in a Tecan Infinite 200 Pro multiwell plate using an excitation wavelength of 355 nm and an emission wavelength of 405 nm. Fluorescence measurements were obtained every 30 s for 10 min, and the degree of OM permeabilisation, referred to as the NPN Uptake Factor, was calculated using the following formula:<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mo>−</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mo>−</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec><sec id="s4-9"><title>CM disruption assay</title><p>To measure CM disruption of whole cells, bacteria grown to stationary-phase overnight were washed and inoculated into 3 ml MHB containing the relevant antibiotics. Cultures were incubated at 37°C with shaking (180 r.p.m.) for up to 8 hr, and every 30 min, aliquots (200 μl) were taken and bacteria isolated by centrifugation (12,300 × <italic>g</italic>, 3 min). Cells were then washed in sterile PBS before being added to the wells of a black-walled microtitre plate, and PI (Sigma-Aldrich) was added to each well at a final concentration of 2.5 μM. Fluorescence was measured immediately in a Tecan Infinite 200 Pro multiwell plate reader (excitation at 535 nm, emission at 617 nm). To measure disruption of the CM in spheroplasts, spheroplasts of <italic>E. coli</italic> and <italic>P. aeruginosa</italic> generated as detailed above were washed by centrifugation (4000 × <italic>g</italic>, 5 min) and resuspension in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose. Spheroplast samples (20 µl) were then added in the wells of a black-walled microtitre plate to 180 µl of Tris buffer (0.03 M, pH 8.0) containing 20% sucrose, the relevant antibiotics, and PI at a final concentration of 0.25 μM. The microtitre plate was incubated with shaking (180 r.p.m.) at 37°C for up to 8 hr in a Tecan Infinite 200 Pro multiwell plate reader and fluorescence (excitation at 535 nm, emission at 617 nm) measured every 15 min using a gain of 80 or 100. For both whole bacterial cells and spheroplasts, to account for differences in fluorescence values arising from variations in cell number, relative fluorescence unit (r.f.u.) measurements were corrected for OD at 600 nm.</p></sec><sec id="s4-10"><title>Determination of bacterial lysis</title><p>In the case of whole bacterial cells, washed stationary-phase bacteria were inoculated into 3 ml CA-MHB containing the relevant antibiotics, as described above. Cultures were then placed in a shaking incubator (37°C, 180 r.p.m.) for 8 hr, and every 30 min, samples (200 μl) were transferred to a microtitre plate, where OD<sub>595nm</sub> measurements were obtained using a Bio-Rad iMark microplate absorbance reader. For spheroplasts, washed spheroplasts (20 µl) were added to 180 µl of Tris buffer (0.03 M, pH 8.0) containing 20% sucrose and the relevant antibiotics in a microtitre plate as detailed above. The microtitre plate was incubated for up to 8 hr at 37°C with shaking (180 r.p.m.) in a Tecan Infinite 200 Pro multiwell plate reader, and readings of OD<sub>600nm</sub> were made every 15 min.</p></sec><sec id="s4-11"><title>Determination of membrane fluidity</title><p>The fluidity of the CM of spheroplasts was assessed using the fluorescent dye Laurdan, as previously described (<xref ref-type="bibr" rid="bib52">Müller et al., 2016</xref>). Washed spheroplasts of <italic>E. coli</italic> (500 µl) prepared as described above were incubated at room temperature for 5 min in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose and Laurdan at a final concentration of 100 µM. Spheroplast samples were washed by three rounds of centrifugation (4000 × <italic>g</italic>, 5 min) and resuspension in Tris buffer containing 20% sucrose, then 200 µl was transferred to the wells of a black-walled microtitre plate. Membrane fluidity was measured using a Tecan Infinite 200 Pro multiwell plate reader, with fluorescence determined using an excitation wavelength of 330 nm, and emission wavelengths of 460 nm and 500 nm. Generalised Polarisation (GP) values were calculated using the following formula:<disp-formula id="equ2"><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mtext> </mml:mtext><mml:mn>460</mml:mn><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mo>−</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mtext> </mml:mtext><mml:mn>500</mml:mn><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mtext> </mml:mtext><mml:mn>460</mml:mn><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mtext> </mml:mtext><mml:mn>500</mml:mn><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>A higher GP value indicated a membrane with reduced fluidity, with altered water penetration into the membrane affecting the fluorescence of the Laurdan dye.</p></sec><sec id="s4-12"><title>Determination of membrane charge</title><p>The charge of the CM of spheroplasts was measured using FITC-labelled Poly-L-Lysine (PLL) (<xref ref-type="bibr" rid="bib32">Jones et al., 2008</xref>). Washed <italic>E. coli</italic> spheroplasts (300 µl) generated as described above were incubated in the dark for 10 min at room temperature in Tris buffer (0.03 M, pH 8.0) containing 20% sucrose and FITC-PLL at a final concentration of 20 µg ml<sup>−1</sup>. To remove any unbound PLL, spheroplasts were subsequently washed thoroughly by three rounds of centrifugation (4000 × <italic>g</italic>, 5 min) and resuspension in Tris buffer containing 20% sucrose. Spheroplast samples (200 µl) were seeded into the wells of a black-walled microtitre plate, and FITC fluorescence was quantified in a Tecan Infinite 200 Pro multiwell plate reader (excitation at 490 nm, emission at 525 nm). Reduced PLL binding to the surface of spheroplasts indicated a more positively charged membrane, with the cationic FITC fluorophore having less affinity for the CM.</p></sec><sec id="s4-13"><title>Determination of LPS concentration by Limulus Amebocyte Lysate assay</title><p>Stationary-phase bacteria grown overnight were washed and grown for 2 hr, before conversion to spheroplasts as described above. During formation of spheroplasts, the OM extracted from the bacterial cells was recovered, and the concentration of LPS in the OM, as well as the concentration of LPS in the CM of spheroplasts, was determined using the chromogenic Limulus Amebocyte Lysate (LAL) assay (all reagents from Thermo Fisher Scientific) as described previously (<xref ref-type="bibr" rid="bib37">Lam et al., 2014</xref>). OM samples and spheroplasts lysed by freeze-thaw to release LPS were diluted in 10-fold steps, and 50 μl of each sample was equilibrated to 37°C and loaded into the wells of a microtitre plate at the same temperature. LAL reagent (50 μl) was added to each well, and the mixture incubated at 37°C for 10 min. Chromogenic substrate solution (100 μl, 2 mM) was subsequently added to each well and the microtitre plate was incubated for a further 6 min at 37°C. The enzymatic reaction was stopped by adding 50 μl of 25% acetic acid to each well, and the presence of LPS was determined by measuring absorbance at 405 nm in a Tecan Infinite 200 Pro multiwell plate reader. A standard curve was generated using an <italic>E. coli</italic> endotoxin standard stock solution, which enabled the conversion of A<sub>405nm</sub> values into concentrations of LPS.</p></sec><sec id="s4-14"><title>Determination of bactericidal activity of antibiotics</title><p>As described above, stationary-phase bacteria grown overnight were washed twice and added at a final inoculum of 10<sup>8</sup> c.f.u. ml<sup>−1</sup> to 3 ml CA-MHB containing colistin and/or murepavadin. Cultures were incubated with shaking (37°C, 180 r.p.m.) for up to 8 hr. Bacterial survival was determined after 2, 4, 6, and 8 hr by serially diluting cultures in 10-fold steps in 200 μl sterile PBS (VWR International, USA), before enumeration of c.f.u. counts on MHA plates.</p></sec><sec id="s4-15"><title>Murine lung infection model</title><p>The use of mice was performed under the authority of the UK Home Office outlined in the Animals (Scientific Procedures) Act 1986 after ethical review by Imperial College London Animal Welfare and Ethical Review Body (PPL 70/7969). Wild-type C57BL/6 mice were purchased from Charles River (UK). All mice were female and aged between 6 and 8 weeks. Mice were housed with five per cage with Aspen chip 2 bedding and 12 h light/dark cycles at 20–22°C. Mice were randomly assigned to experimental groups. Water was provided ad libitum and mice were fed RM1 (Special Diet Services). To establish colonisation of the lungs, mice were anesthetised and intranasally inoculated with 10<sup>7</sup> c.f.u. of <italic>P. aeruginosa</italic> PA14 in 50 μl of PBS, as described previously (<xref ref-type="bibr" rid="bib16">Clarke, 2014</xref>; <xref ref-type="bibr" rid="bib11">Brown et al., 2017</xref>). Infection was allowed to establish for 5 hr, before mice were again anaesthetised and treated via the intranasal route with 50 μl of PBS alone, or PBS containing colistin (5 mg kg<sup>−1</sup>), murepavadin (0.25 mg kg<sup>−1</sup>), or a combination of colistin and murepavadin for 3 hr. To enumerate bacterial load in the lungs, mice were humanely sacrificed, their lungs removed and homogenised in PBS, and then plated onto Pseudomonas isolation agar (Thermo Fisher Scientific).</p></sec><sec id="s4-16"><title>Statistical analyses</title><p>Experiments were performed on at least three independent occasions, and the resulting data are presented as the arithmetic mean of these biological repeats, unless stated otherwise. Error bars, where shown, represent the standard deviation of the mean. For single comparisons, a two-tailed Student’s <italic>t</italic>-test was used to analyse the data. For multiple comparisons at a single time point or concentration, data were analysed using a one-way analysis of variance (ANOVA) or a Kruskal–Wallis test. Where data were obtained at several different time points or concentrations, a two-way ANOVA was used for statistical analyses. Appropriate post hoc tests (Dunnett’s, Tukey’s, Sidak’s, Dunn’s) were carried out to correct for multiple comparisons, with details provided in the figure legends. Asterisks on graphs indicate significant differences between data, and the corresponding p-values are reported in the figure legend. All statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software Inc, USA).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>Aishwarya Krishna, Laura Nolan, Alain Filloux, Ollie Fletcher (all Imperial College London), and Alireza Abdolrasouli (Imperial College Healthcare NHS Trust) are gratefully acknowledged for providing bacterial strains. Lisa Haigh (Imperial College London) is thanked for processing and analysing mass spectrometry samples. Vladimir Pelicic (Imperial College London) is thanked for providing access to the Axio Imager.A2 Zeiss microscope. AS is supported by a PhD studentship funded by a Medical Research Council Doctoral Training Award to Imperial College London (MR/N014103/1). AK is funded by the DFG German Research Foundation (KL3191/1-1) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions grant agreement ‘BacDrug’ (838183). MB and MMS gratefully acknowledge support from the Rosetrees Trust (M300-CD1). DAIM and RCDF gratefully acknowledge funding from an MRC Career Development Award (MR/M009505/1). JCD is supported by the NIHR through a Senior Investigator award and the Imperial Biomedical Research Centre (BRC). RM and JCD are supported by Cystic Fibrosis Trust funding. GJL-M is funded by the MRC Confidence in Concept Fund and a ISSF Wellcome Trust Grant (105603/Z/14/Z). TBC is a Sir Henry Dale Fellow jointly funded by the Wellcome Trust and Royal Society (107660/Z/15Z). LEE and AME acknowledge funding from the Wellcome Trust (204337/Z/16/Z). AME also acknowledges support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) and declares funding from Shionogi and Co., Ltd for an unrelated project.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Supervision, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Formal analysis, Supervision, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The use of mice was performed under the authority of the UK Home Office outlined in the Animals (Scientific Procedures) Act 1986 after ethical review by Imperial College London Animal Welfare and Ethical Review Body (PPL 70/7969).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Contains Supplementary Table 1 detailing the minimum inhibitory concentrations (MICs) of colistin and murepavadin against the <italic>P. aeruginosa</italic> strains used in this study.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-65836-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-65836-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Source data for all figures has been deposited at Dryad: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.98sf7m0hh">https://doi.org/10.5061/dryad.98sf7m0hh</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Sabnis</surname><given-names>A</given-names></name><name><surname>Hagart</surname><given-names>KLH</given-names></name><name><surname>Klöckner</surname><given-names>A</given-names></name><name><surname>Becce</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>LE</given-names></name><name><surname>Furniss</surname><given-names>RCD</given-names></name><name><surname>Mavridou</surname><given-names>DAi</given-names></name><name><surname>Murphy</surname><given-names>R</given-names></name><name><surname>Stevens</surname><given-names>MM</given-names></name><name><surname>Davies</surname><given-names>JC</given-names></name><name><surname>Larrouy-Maumus</surname><given-names>GJ</given-names></name><name><surname>Clarke</surname><given-names>TB</given-names></name><name><surname>Edwards</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Data from: Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane</data-title><source>Dryad Digital Repository</source><pub-id assigning-authority="Dryad" pub-id-type="doi">10.5061/dryad.98sf7m0hh</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajiboye</surname> <given-names>TO</given-names></name><name><surname>Skiebe</surname> <given-names>E</given-names></name><name><surname>Wilharm</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Contributions of RecA and RecBCD DNA repair pathways to the oxidative stress response and sensitivity of <italic>Acinetobacter baumannii</italic> to antibiotics</article-title><source>International journal of antimicrobial agents</source><volume>52</volume><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.07.022</pub-id><pub-id pub-id-type="pmid">30081139</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname> <given-names>DG</given-names></name><name><surname>Lambert</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Modes of action of antibacterial agents</article-title><source>Molecular Medical Microbiology</source><volume>1</volume><fpage>583</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-397169-2.00032-9</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andolina</surname> <given-names>G</given-names></name><name><surname>Bencze</surname> <given-names>LC</given-names></name><name><surname>Zerbe</surname> <given-names>K</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name><name><surname>Steinmann</surname> <given-names>J</given-names></name><name><surname>Kocherla</surname> <given-names>H</given-names></name><name><surname>Mondal</surname> <given-names>M</given-names></name><name><surname>Sobek</surname> <given-names>J</given-names></name><name><surname>Moehle</surname> <given-names>K</given-names></name><name><surname>Malojčić</surname> <given-names>G</given-names></name><name><surname>Wollscheid</surname> <given-names>B</given-names></name><name><surname>Robinson</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from <italic>Pseudomonas aeruginosa</italic></article-title><source>ACS chemical biology</source><volume>13</volume><fpage>666</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00822</pub-id><pub-id pub-id-type="pmid">29359918</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname> <given-names>N</given-names></name><name><surname>Tateda</surname> <given-names>K</given-names></name><name><surname>Kikuchi</surname> <given-names>Y</given-names></name><name><surname>Kimura</surname> <given-names>S</given-names></name><name><surname>Miyazaki</surname> <given-names>C</given-names></name><name><surname>Ishii</surname> <given-names>Y</given-names></name><name><surname>Tanabe</surname> <given-names>Y</given-names></name><name><surname>Gejyo</surname> <given-names>F</given-names></name><name><surname>Yamaguchi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant <italic>Pseudomonas aeruginosa</italic></article-title><source>The Journal of antimicrobial chemotherapy</source><volume>63</volume><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn530</pub-id><pub-id pub-id-type="pmid">19147523</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayoub Moubareck</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Polymyxins and bacterial membranes: a review of antibacterial activity and mechanisms of resistance</article-title><source>Membranes</source><volume>10</volume><elocation-id>181</elocation-id><pub-id pub-id-type="doi">10.3390/membranes10080181</pub-id><pub-id pub-id-type="pmid">32784516</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname> <given-names>JR</given-names></name><name><surname>Spilker</surname> <given-names>CM</given-names></name><name><surname>Lewis</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Effects of polymyxin B on mammalian urinary bladder</article-title><source>The Journal of membrane biology</source><volume>154</volume><fpage>119</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1007/s002329900137</pub-id><pub-id pub-id-type="pmid">8929286</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardini</surname> <given-names>F</given-names></name><name><surname>Dale</surname> <given-names>GE</given-names></name><name><surname>Wach</surname> <given-names>A</given-names></name><name><surname>Obrecht</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>WS01-4 pharmacokinetics and pharmacodynamics of murepavadin (POL7080) in neutropenic lung infection models when evaluated by aerosol administration</article-title><source>Journal of Cystic Fibrosis</source><volume>18</volume><elocation-id>S2</elocation-id><pub-id pub-id-type="doi">10.1016/S1569-1993(19)30120-1</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betts</surname> <given-names>JW</given-names></name><name><surname>Sharili</surname> <given-names>AS</given-names></name><name><surname>La Ragione</surname> <given-names>RM</given-names></name><name><surname>Wareham</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>In Vitro Antibacterial Activity of Curcumin-Polymyxin B Combinations against Multidrug-Resistant Bacteria Associated with Traumatic Wound Infections</article-title><source>Journal of natural products</source><volume>79</volume><fpage>1702</fpage><lpage>1706</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.6b00286</pub-id><pub-id pub-id-type="pmid">27295561</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname> <given-names>S</given-names></name><name><surname>Brunel</surname> <given-names>JM</given-names></name><name><surname>Dubus</surname> <given-names>JC</given-names></name><name><surname>Reynaud-Gaubert</surname> <given-names>M</given-names></name><name><surname>Rolain</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Colistin: an update on the antibiotic of the 21st century</article-title><source>Expert review of anti-infective therapy</source><volume>10</volume><fpage>917</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1586/eri.12.78</pub-id><pub-id pub-id-type="pmid">23030331</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan-Krohn</surname> <given-names>T</given-names></name><name><surname>Pironti</surname> <given-names>A</given-names></name><name><surname>Kirby</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae</article-title><source>Antimicrobial agents and chemotherapy</source><volume>62</volume><elocation-id>e00873–18</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.00873-18</pub-id><pub-id pub-id-type="pmid">30061285</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>RL</given-names></name><name><surname>Sequeira</surname> <given-names>RP</given-names></name><name><surname>Clarke</surname> <given-names>TB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The microbiota protects against respiratory infection via GM-CSF signaling</article-title><source>Nature communications</source><volume>8</volume><elocation-id>1512</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01803-x</pub-id><pub-id pub-id-type="pmid">29142211</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cajal</surname> <given-names>Y</given-names></name><name><surname>Rogers</surname> <given-names>J</given-names></name><name><surname>Berg</surname> <given-names>OG</given-names></name><name><surname>Jain</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Intermembrane molecular contacts by polymyxin B mediate exchange of phospholipids</article-title><source>Biochemistry</source><volume>35</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1021/bi9512408</pub-id><pub-id pub-id-type="pmid">8555188</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname> <given-names>LM</given-names></name><name><surname>Gaballa</surname> <given-names>A</given-names></name><name><surname>Guldimann</surname> <given-names>C</given-names></name><name><surname>Sullivan</surname> <given-names>G</given-names></name><name><surname>Henderson</surname> <given-names>LO</given-names></name><name><surname>Wiedmann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of Novel Mobilized Colistin Resistance Gene <italic>mcr-9</italic> in a Multidrug-Resistant, Colistin-Susceptible <italic>Salmonella enterica</italic> Serotype Typhimurium Isolate</article-title><source>mBio</source><volume>10</volume><elocation-id>e00853–19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00853-19</pub-id><pub-id pub-id-type="pmid">31064835</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Weisshaar</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oxidative stress induced in <italic>E. coli</italic> by the human antimicrobial peptide LL-37</article-title><source>PLOS pathogens</source><volume>13</volume><elocation-id>e1006481</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006481</pub-id><pub-id pub-id-type="pmid">28665988</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clairfeuille</surname> <given-names>T</given-names></name><name><surname>Buchholz</surname> <given-names>KR</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Verschueren</surname> <given-names>E</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Sangaraju</surname> <given-names>D</given-names></name><name><surname>Park</surname> <given-names>S</given-names></name><name><surname>Noland</surname> <given-names>CL</given-names></name><name><surname>Storek</surname> <given-names>KM</given-names></name><name><surname>Nickerson</surname> <given-names>NN</given-names></name><name><surname>Martin</surname> <given-names>L</given-names></name><name><surname>Dela Vega</surname> <given-names>T</given-names></name><name><surname>Miu</surname> <given-names>A</given-names></name><name><surname>Reeder</surname> <given-names>J</given-names></name><name><surname>Ruiz-Gonzalez</surname> <given-names>M</given-names></name><name><surname>Swem</surname> <given-names>D</given-names></name><name><surname>Han</surname> <given-names>G</given-names></name><name><surname>DePonte</surname> <given-names>DP</given-names></name><name><surname>Hunter</surname> <given-names>MS</given-names></name><name><surname>Gati</surname> <given-names>C</given-names></name><name><surname>Shahidi-Latham</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Skelton</surname> <given-names>N</given-names></name><name><surname>Sellers</surname> <given-names>BD</given-names></name><name><surname>Skippington</surname> <given-names>E</given-names></name><name><surname>Sandoval</surname> <given-names>W</given-names></name><name><surname>Hanan</surname> <given-names>EJ</given-names></name><name><surname>Payandeh</surname> <given-names>J</given-names></name><name><surname>Rutherford</surname> <given-names>ST</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of the essential inner membrane lipopolysaccharide-PbgA complex</article-title><source>Nature</source><volume>584</volume><fpage>479</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2597-x</pub-id><pub-id pub-id-type="pmid">32788728</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname> <given-names>TB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands</article-title><source>Infection and immunity</source><volume>82</volume><fpage>4596</fpage><lpage>4606</lpage><pub-id pub-id-type="doi">10.1128/IAI.02212-14</pub-id><pub-id pub-id-type="pmid">25135683</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausell</surname> <given-names>A</given-names></name><name><surname>Rabanal</surname> <given-names>F</given-names></name><name><surname>Garcia-Subirats</surname> <given-names>M</given-names></name><name><surname>Asunción Alsina</surname> <given-names>M</given-names></name><name><surname>Cajal</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Membrane association and contact formation by a synthetic analogue of polymyxin B and its fluorescent derivatives</article-title><source>The Journal of Physical Chemistry B</source><volume>110</volume><fpage>4465</fpage><lpage>4471</lpage><pub-id pub-id-type="doi">10.1021/jp0551972</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausell</surname> <given-names>A</given-names></name><name><surname>Garcia-Subirats</surname> <given-names>M</given-names></name><name><surname>Pujol</surname> <given-names>M</given-names></name><name><surname>Busquets</surname> <given-names>MA</given-names></name><name><surname>Rabanal</surname> <given-names>F</given-names></name><name><surname>Cajal</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides</article-title><source>The journal of physical chemistry. B</source><volume>111</volume><fpage>551</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1021/jp064757+</pub-id><pub-id pub-id-type="pmid">17228913</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'amato</surname> <given-names>RF</given-names></name><name><surname>Thornsberry</surname> <given-names>C</given-names></name><name><surname>Baker</surname> <given-names>CN</given-names></name><name><surname>Kirven</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Effect of calcium and magnesium ions on the susceptibility of <italic>Pseudomonas</italic> species to tetracycline, gentamicin polymyxin B, and carbenicillin</article-title><source>Antimicrobial agents and chemotherapy</source><volume>7</volume><fpage>596</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1128/aac.7.5.596</pub-id><pub-id pub-id-type="pmid">167658</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deris</surname> <given-names>ZZ</given-names></name><name><surname>Akter</surname> <given-names>J</given-names></name><name><surname>Sivanesan</surname> <given-names>S</given-names></name><name><surname>Roberts</surname> <given-names>KD</given-names></name><name><surname>Thompson</surname> <given-names>PE</given-names></name><name><surname>Nation</surname> <given-names>RL</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Velkov</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A secondary mode of action of polymyxins against Gram-negative Bacteria involves the inhibition of NADH-quinone oxidoreductase activity</article-title><source>The Journal of Antibiotics</source><volume>67</volume><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/ja.2013.111</pub-id><pub-id pub-id-type="pmid">24169795</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dortet</surname> <given-names>L</given-names></name><name><surname>Bonnin</surname> <given-names>RA</given-names></name><name><surname>Pennisi</surname> <given-names>I</given-names></name><name><surname>Gauthier</surname> <given-names>L</given-names></name><name><surname>Jousset</surname> <given-names>AB</given-names></name><name><surname>Dabos</surname> <given-names>L</given-names></name><name><surname>Furniss</surname> <given-names>RCD</given-names></name><name><surname>Mavridou</surname> <given-names>DAI</given-names></name><name><surname>Bogaerts</surname> <given-names>P</given-names></name><name><surname>Glupczynski</surname> <given-names>Y</given-names></name><name><surname>Potron</surname> <given-names>A</given-names></name><name><surname>Plesiat</surname> <given-names>P</given-names></name><name><surname>Beyrouthy</surname> <given-names>R</given-names></name><name><surname>Robin</surname> <given-names>F</given-names></name><name><surname>Bonnet</surname> <given-names>R</given-names></name><name><surname>Naas</surname> <given-names>T</given-names></name><name><surname>Filloux</surname> <given-names>A</given-names></name><name><surname>Larrouy-Maumus</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rapid detection and discrimination of chromosome- and MCR-plasmid-mediated resistance to polymyxins by MALDI-TOF MS in <italic>Escherichia coli</italic>: the MALDIxin test</article-title><source>The Journal of antimicrobial chemotherapy</source><volume>73</volume><fpage>3359</fpage><lpage>3367</lpage><pub-id pub-id-type="doi">10.1093/jac/dky330</pub-id><pub-id pub-id-type="pmid">30184212</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Sayed Ahmed</surname> <given-names>MAE</given-names></name><name><surname>Zhong</surname> <given-names>LL</given-names></name><name><surname>Shen</surname> <given-names>C</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Doi</surname> <given-names>Y</given-names></name><name><surname>Tian</surname> <given-names>GB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019)</article-title><source>Emerging microbes &amp; infections</source><volume>9</volume><fpage>868</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1754133</pub-id><pub-id pub-id-type="pmid">32284036</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falagas</surname> <given-names>ME</given-names></name><name><surname>Rafailidis</surname> <given-names>PI</given-names></name><name><surname>Ioannidou</surname> <given-names>E</given-names></name><name><surname>Alexiou</surname> <given-names>VG</given-names></name><name><surname>Matthaiou</surname> <given-names>DK</given-names></name><name><surname>Karageorgopoulos</surname> <given-names>DE</given-names></name><name><surname>Kapaskelis</surname> <given-names>A</given-names></name><name><surname>Nikita</surname> <given-names>D</given-names></name><name><surname>Michalopoulos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients</article-title><source>International journal of antimicrobial agents</source><volume>35</volume><fpage>194</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2009.10.005</pub-id><pub-id pub-id-type="pmid">20006471</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fivenson</surname> <given-names>EM</given-names></name><name><surname>Bernhardt</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An Essential Membrane Protein Modulates the Proteolysis of LpxC to Control Lipopolysaccharide Synthesis in <italic>Escherichia coli</italic></article-title><source>mBio</source><volume>11</volume><elocation-id>e00939–20</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00939-20</pub-id><pub-id pub-id-type="pmid">32430473</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname> <given-names>L</given-names></name><name><surname>Wan</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>L</given-names></name><name><surname>Fang</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Polymyxin B Loosens Lipopolysaccharide Bilayer but Stiffens Phospholipid Bilayer</article-title><source>Biophysical journal</source><volume>118</volume><fpage>138</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2019.11.008</pub-id><pub-id pub-id-type="pmid">31812355</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furniss</surname> <given-names>RCD</given-names></name><name><surname>Dortet</surname> <given-names>L</given-names></name><name><surname>Bolland</surname> <given-names>W</given-names></name><name><surname>Drews</surname> <given-names>O</given-names></name><name><surname>Sparbier</surname> <given-names>K</given-names></name><name><surname>Bonnin</surname> <given-names>RA</given-names></name><name><surname>Filloux</surname> <given-names>A</given-names></name><name><surname>Kostrzewa</surname> <given-names>M</given-names></name><name><surname>Mavridou</surname> <given-names>DAI</given-names></name><name><surname>Larrouy-Maumus</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Detection of Colistin Resistance in <italic>Escherichia coli</italic> by Use of the MALDI Biotyper Sirius Mass Spectrometry System</article-title><source>Journal of clinical microbiology</source><volume>57</volume><elocation-id>e01427–19</elocation-id><pub-id pub-id-type="doi">10.1128/JCM.01427-19</pub-id><pub-id pub-id-type="pmid">31597744</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname> <given-names>SK</given-names></name><name><surname>Singh</surname> <given-names>O</given-names></name><name><surname>Juneja</surname> <given-names>D</given-names></name><name><surname>Tyagi</surname> <given-names>N</given-names></name><name><surname>Khurana</surname> <given-names>AS</given-names></name><name><surname>Qamra</surname> <given-names>A</given-names></name><name><surname>Motlekar</surname> <given-names>S</given-names></name><name><surname>Barkate</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence</article-title><source>Critical care research and practice</source><volume>2017</volume><elocation-id>3635609</elocation-id><pub-id pub-id-type="doi">10.1155/2017/3635609</pub-id><pub-id pub-id-type="pmid">28761764</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guest</surname> <given-names>RL</given-names></name><name><surname>Samé Guerra</surname> <given-names>D</given-names></name><name><surname>Wissler</surname> <given-names>M</given-names></name><name><surname>Grimm</surname> <given-names>J</given-names></name><name><surname>Silhavy</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>YejM Modulates Activity of the YciM/FtsH Protease Complex To Prevent Lethal Accumulation of Lipopolysaccharide</article-title><source>mBio</source><volume>11</volume><elocation-id>e00598–20</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00598-20</pub-id><pub-id pub-id-type="pmid">32291302</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helander</surname> <given-names>IM</given-names></name><name><surname>Mattila-Sandholm</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Fluorometric assessment of gram-negative bacterial permeabilization</article-title><source>Journal of applied microbiology</source><volume>88</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2672.2000.00971.x</pub-id><pub-id pub-id-type="pmid">10735988</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppe Parr</surname> <given-names>KA</given-names></name><name><surname>Hađina</surname> <given-names>S</given-names></name><name><surname>Kilburg-Basnyat</surname> <given-names>B</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Chavez</surname> <given-names>D</given-names></name><name><surname>Thorne</surname> <given-names>PS</given-names></name><name><surname>Weiss</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Modification of sample processing for the Limulus amebocyte lysate assay enhances detection of inflammogenic endotoxin in intact bacteria and organic dust</article-title><source>Innate immunity</source><volume>23</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1177/1753425917694084</pub-id><pub-id pub-id-type="pmid">28359219</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname> <given-names>AB</given-names></name><name><surname>Bartholomew</surname> <given-names>TL</given-names></name><name><surname>Marciszewska</surname> <given-names>NP</given-names></name><name><surname>Bonten</surname> <given-names>MJM</given-names></name><name><surname>Willems</surname> <given-names>RJL</given-names></name><name><surname>Bengoechea</surname> <given-names>JA</given-names></name><name><surname>van Schaik</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nonclonal Emergence of Colistin Resistance Associated with Mutations in the BasRS Two-Component System in <italic>Escherichia coli</italic> Bloodstream Isolates</article-title><source>mSphere</source><volume>5</volume><elocation-id>e00143–20</elocation-id><pub-id pub-id-type="doi">10.1128/mSphere.00143-20</pub-id><pub-id pub-id-type="pmid">32161146</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>T</given-names></name><name><surname>Yeaman</surname> <given-names>MR</given-names></name><name><surname>Sakoulas</surname> <given-names>G</given-names></name><name><surname>Yang</surname> <given-names>SJ</given-names></name><name><surname>Proctor</surname> <given-names>RA</given-names></name><name><surname>Sahl</surname> <given-names>HG</given-names></name><name><surname>Schrenzel</surname> <given-names>J</given-names></name><name><surname>Xiong</surname> <given-names>YQ</given-names></name><name><surname>Bayer</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Failures in clinical treatment of <italic>Staphylococcus aureus</italic> Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding</article-title><source>Antimicrobial agents and chemotherapy</source><volume>52</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1128/AAC.00719-07</pub-id><pub-id pub-id-type="pmid">17954690</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karampitsakos</surname> <given-names>T</given-names></name><name><surname>Papaioannou</surname> <given-names>O</given-names></name><name><surname>Kaponi</surname> <given-names>M</given-names></name><name><surname>Kozanidou</surname> <given-names>A</given-names></name><name><surname>Hillas</surname> <given-names>G</given-names></name><name><surname>Stavropoulou</surname> <given-names>E</given-names></name><name><surname>Bouros</surname> <given-names>D</given-names></name><name><surname>Dimakou</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis</article-title><source>Pulmonary pharmacology &amp; therapeutics</source><volume>60</volume><elocation-id>101885</elocation-id><pub-id pub-id-type="doi">10.1016/j.pupt.2019.101885</pub-id><pub-id pub-id-type="pmid">31891761</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karas</surname> <given-names>JA</given-names></name><name><surname>Carter</surname> <given-names>GP</given-names></name><name><surname>Howden</surname> <given-names>BP</given-names></name><name><surname>Turner</surname> <given-names>AM</given-names></name><name><surname>Paulin</surname> <given-names>OKA</given-names></name><name><surname>Swarbrick</surname> <given-names>JD</given-names></name><name><surname>Baker</surname> <given-names>MA</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Velkov</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure-Activity relationships of daptomycin lipopeptides</article-title><source>Journal of Medicinal Chemistry</source><volume>63</volume><fpage>13266</fpage><lpage>13290</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00780</pub-id><pub-id pub-id-type="pmid">32687352</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khadka</surname> <given-names>NK</given-names></name><name><surname>Aryal</surname> <given-names>CM</given-names></name><name><surname>Pan</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lipopolysaccharide-Dependent Membrane Permeation and Lipid Clustering Caused by Cyclic Lipopeptide Colistin</article-title><source>ACS omega</source><volume>3</volume><fpage>17828</fpage><lpage>17834</lpage><pub-id pub-id-type="doi">10.1021/acsomega.8b02260</pub-id><pub-id pub-id-type="pmid">30613815</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouidhi</surname> <given-names>B</given-names></name><name><surname>Zmantar</surname> <given-names>T</given-names></name><name><surname>Mahdouani</surname> <given-names>K</given-names></name><name><surname>Hentati</surname> <given-names>H</given-names></name><name><surname>Bakhrouf</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Antibiotic resistance and adhesion properties of oral <italic>Enterococci</italic> associated to dental caries</article-title><source>BMC microbiology</source><volume>11</volume><elocation-id>155</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-11-155</pub-id><pub-id pub-id-type="pmid">21714920</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname> <given-names>JS</given-names></name><name><surname>Anderson</surname> <given-names>EM</given-names></name><name><surname>Hao</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>LPS quantitation procedures</article-title><source>Methods in molecular biology</source><volume>1149</volume><fpage>375</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-0473-0_31</pub-id><pub-id pub-id-type="pmid">24818921</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>DG</given-names></name><name><surname>Urbach</surname> <given-names>JM</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Liberati</surname> <given-names>NT</given-names></name><name><surname>Feinbaum</surname> <given-names>RL</given-names></name><name><surname>Miyata</surname> <given-names>S</given-names></name><name><surname>Diggins</surname> <given-names>LT</given-names></name><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Saucier</surname> <given-names>M</given-names></name><name><surname>Déziel</surname> <given-names>E</given-names></name><name><surname>Friedman</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Grills</surname> <given-names>G</given-names></name><name><surname>Montgomery</surname> <given-names>K</given-names></name><name><surname>Kucherlapati</surname> <given-names>R</given-names></name><name><surname>Rahme</surname> <given-names>LG</given-names></name><name><surname>Ausubel</surname> <given-names>FM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Genomic analysis reveals that <italic>Pseudomonas aeruginosa</italic> virulence is combinatorial</article-title><source>Genome Biology</source><volume>7</volume><elocation-id>R90</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2006-7-10-r90</pub-id><pub-id pub-id-type="pmid">17038190</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>KJ</given-names></name><name><surname>Lee</surname> <given-names>WS</given-names></name><name><surname>Hwang</surname> <given-names>A</given-names></name><name><surname>Moon</surname> <given-names>J</given-names></name><name><surname>Kang</surname> <given-names>T</given-names></name><name><surname>Park</surname> <given-names>K</given-names></name><name><surname>Jeong</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Simple and rapid detection of bacteria using a nuclease-responsive DNA probe</article-title><source>The Analyst</source><volume>143</volume><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1039/c7an01384a</pub-id><pub-id pub-id-type="pmid">29210381</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehman</surname> <given-names>KM</given-names></name><name><surname>Grabowicz</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Countering Gram-Negative Antibiotic Resistance: Recent Progress in Disrupting the Outer Membrane with Novel Therapeutics</article-title><source>Antibiotics</source><volume>8</volume><elocation-id>E163</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8040163</pub-id><pub-id pub-id-type="pmid">31554212</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Orlando</surname> <given-names>BJ</given-names></name><name><surname>Liao</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis of lipopolysaccharide extraction by the LptB<sub>2</sub>FGC complex</article-title><source>Nature</source><volume>567</volume><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1025-6</pub-id><pub-id pub-id-type="pmid">30894744</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Velkov</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Polymyxins: mode of action, in polymyxin antibiotics: from laboratory bench to bedside</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1145</volume><fpage>37</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-16373-0</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linden</surname> <given-names>PK</given-names></name><name><surname>Kusne</surname> <given-names>S</given-names></name><name><surname>Coley</surname> <given-names>K</given-names></name><name><surname>Fontes</surname> <given-names>P</given-names></name><name><surname>Kramer</surname> <given-names>DJ</given-names></name><name><surname>Paterson</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant <italic>Pseudomonas aeruginosa</italic></article-title><source>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</source><volume>37</volume><elocation-id>e154–160</elocation-id><pub-id pub-id-type="doi">10.1086/379611</pub-id><pub-id pub-id-type="pmid">14614688</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>YY</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Walsh</surname> <given-names>TR</given-names></name><name><surname>Yi</surname> <given-names>LX</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Spencer</surname> <given-names>J</given-names></name><name><surname>Doi</surname> <given-names>Y</given-names></name><name><surname>Tian</surname> <given-names>G</given-names></name><name><surname>Dong</surname> <given-names>B</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>LF</given-names></name><name><surname>Gu</surname> <given-names>D</given-names></name><name><surname>Ren</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Lv</surname> <given-names>L</given-names></name><name><surname>He</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Liang</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>JH</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study</article-title><source>The Lancet. Infectious diseases</source><volume>16</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00424-7</pub-id><pub-id pub-id-type="pmid">26603172</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname> <given-names>LN</given-names></name><name><surname>Ward</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title><italic>Escherichia coli</italic> K1 invasion of human brain microvascular endothelial cells</article-title><source>Methods in enzymology</source><volume>506</volume><fpage>93</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-391856-7.00030-5</pub-id><pub-id pub-id-type="pmid">22341221</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacNair</surname> <given-names>CR</given-names></name><name><surname>Stokes</surname> <given-names>JM</given-names></name><name><surname>Carfrae</surname> <given-names>LA</given-names></name><name><surname>Fiebig-Comyn</surname> <given-names>AA</given-names></name><name><surname>Coombes</surname> <given-names>BK</given-names></name><name><surname>Mulvey</surname> <given-names>MR</given-names></name><name><surname>Brown</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Overcoming <italic>mcr-1</italic> mediated colistin resistance with colistin in combination with other antibiotics</article-title><source>Nature communications</source><volume>9</volume><elocation-id>458</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-02875-z</pub-id><pub-id pub-id-type="pmid">29386620</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandler</surname> <given-names>MD</given-names></name><name><surname>Baidin</surname> <given-names>V</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Pahil</surname> <given-names>KS</given-names></name><name><surname>Owens</surname> <given-names>TW</given-names></name><name><surname>Kahne</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport</article-title><source>Journal of the American Chemical Society</source><volume>140</volume><fpage>6749</fpage><lpage>6753</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b02283</pub-id><pub-id pub-id-type="pmid">29746111</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname> <given-names>LS</given-names></name><name><surname>Roberts</surname> <given-names>KD</given-names></name><name><surname>Nation</surname> <given-names>RL</given-names></name><name><surname>Thompson</surname> <given-names>PE</given-names></name><name><surname>Velkov</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Tor</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Polymyxins and analogues bind to ribosomal RNA and interfere with eukaryotic translation in vitro</article-title><source>Chembiochem : a European journal of chemical biology</source><volume>14</volume><fpage>2083</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1002/cbic.201300496</pub-id><pub-id pub-id-type="pmid">24105917</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melchers</surname> <given-names>MJ</given-names></name><name><surname>Teague</surname> <given-names>J</given-names></name><name><surname>Warn</surname> <given-names>P</given-names></name><name><surname>Hansen</surname> <given-names>J</given-names></name><name><surname>Bernardini</surname> <given-names>F</given-names></name><name><surname>Wach</surname> <given-names>A</given-names></name><name><surname>Obrecht</surname> <given-names>D</given-names></name><name><surname>Dale</surname> <given-names>GE</given-names></name><name><surname>Mouton</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models</article-title><source>Antimicrobial agents and chemotherapy</source><volume>63</volume><elocation-id>e01699–18</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01699-18</pub-id><pub-id pub-id-type="pmid">30642931</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffatt</surname> <given-names>JH</given-names></name><name><surname>Harper</surname> <given-names>M</given-names></name><name><surname>Harrison</surname> <given-names>P</given-names></name><name><surname>Hale</surname> <given-names>JD</given-names></name><name><surname>Vinogradov</surname> <given-names>E</given-names></name><name><surname>Seemann</surname> <given-names>T</given-names></name><name><surname>Henry</surname> <given-names>R</given-names></name><name><surname>Crane</surname> <given-names>B</given-names></name><name><surname>St Michael</surname> <given-names>F</given-names></name><name><surname>Cox</surname> <given-names>AD</given-names></name><name><surname>Adler</surname> <given-names>B</given-names></name><name><surname>Nation</surname> <given-names>RL</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Boyce</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Colistin resistance in <italic>Acinetobacter baumannii</italic> is mediated by complete loss of lipopolysaccharide production</article-title><source>Antimicrobial agents and chemotherapy</source><volume>54</volume><fpage>4971</fpage><lpage>4977</lpage><pub-id pub-id-type="doi">10.1128/AAC.00834-10</pub-id><pub-id pub-id-type="pmid">20855724</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname> <given-names>RA</given-names></name><name><surname>Hancock</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Involvement of outer membrane of <italic>Pseudomonas cepacia</italic> in aminoglycoside and polymyxin resistance</article-title><source>Antimicrobial agents and chemotherapy</source><volume>30</volume><fpage>923</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1128/aac.30.6.923</pub-id><pub-id pub-id-type="pmid">3028253</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname> <given-names>A</given-names></name><name><surname>Wenzel</surname> <given-names>M</given-names></name><name><surname>Strahl</surname> <given-names>H</given-names></name><name><surname>Grein</surname> <given-names>F</given-names></name><name><surname>Saaki</surname> <given-names>TNV</given-names></name><name><surname>Kohl</surname> <given-names>B</given-names></name><name><surname>Siersma</surname> <given-names>T</given-names></name><name><surname>Bandow</surname> <given-names>JE</given-names></name><name><surname>Sahl</surname> <given-names>HG</given-names></name><name><surname>Schneider</surname> <given-names>T</given-names></name><name><surname>Hamoen</surname> <given-names>LW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains</article-title><source>PNAS</source><volume>113</volume><fpage>E7077</fpage><lpage>E7086</lpage><pub-id pub-id-type="doi">10.1073/pnas.1611173113</pub-id><pub-id pub-id-type="pmid">27791134</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nang</surname> <given-names>SC</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Velkov</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The rise and spread of <italic>mcr</italic> plasmid-mediated polymyxin resistance</article-title><source>Critical reviews in microbiology</source><volume>45</volume><fpage>131</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1080/1040841X.2018.1492902</pub-id><pub-id pub-id-type="pmid">31122100</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Rourke</surname> <given-names>A</given-names></name><name><surname>Beyhan</surname> <given-names>S</given-names></name><name><surname>Choi</surname> <given-names>Y</given-names></name><name><surname>Morales</surname> <given-names>P</given-names></name><name><surname>Chan</surname> <given-names>AP</given-names></name><name><surname>Espinoza</surname> <given-names>JL</given-names></name><name><surname>Dupont</surname> <given-names>CL</given-names></name><name><surname>Meyer</surname> <given-names>KJ</given-names></name><name><surname>Spoering</surname> <given-names>A</given-names></name><name><surname>Lewis</surname> <given-names>K</given-names></name><name><surname>Nierman</surname> <given-names>WC</given-names></name><name><surname>Nelson</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanism-of-Action Classification of Antibiotics by Global Transcriptome Profiling</article-title><source>Antimicrobial agents and chemotherapy</source><volume>64</volume><elocation-id>e01207–01219</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01207-19</pub-id><pub-id pub-id-type="pmid">31907190</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odds</surname> <given-names>FC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Synergy, antagonism, and what the chequerboard puts between them</article-title><source>The Journal of antimicrobial chemotherapy</source><volume>52</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1093/jac/dkg301</pub-id><pub-id pub-id-type="pmid">12805255</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>S</given-names></name><name><surname>Sherman</surname> <given-names>DJ</given-names></name><name><surname>Silhavy</surname> <given-names>TJ</given-names></name><name><surname>Ruiz</surname> <given-names>N</given-names></name><name><surname>Kahne</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Lipopolysaccharide transport and assembly at the outer membrane: the PEZ model</article-title><source>Nature reviews. Microbiology</source><volume>14</volume><fpage>337</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.25</pub-id><pub-id pub-id-type="pmid">27026255</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname> <given-names>MJ</given-names></name><name><surname>Gander</surname> <given-names>JE</given-names></name><name><surname>Parisi</surname> <given-names>E</given-names></name><name><surname>Carson</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Mechanism of assembly of the outer membrane of <italic>Salmonella typhimurium</italic>. Isolation and characterization of cytoplasmic and outer membrane</article-title><source>The Journal of biological chemistry</source><volume>247</volume><fpage>3962</fpage><lpage>3972</lpage><pub-id pub-id-type="pmid">4555955</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname> <given-names>M</given-names></name><name><surname>Daikos</surname> <given-names>GL</given-names></name><name><surname>Durante-Mangoni</surname> <given-names>E</given-names></name><name><surname>Yahav</surname> <given-names>D</given-names></name><name><surname>Carmeli</surname> <given-names>Y</given-names></name><name><surname>Benattar</surname> <given-names>YD</given-names></name><name><surname>Skiada</surname> <given-names>A</given-names></name><name><surname>Andini</surname> <given-names>R</given-names></name><name><surname>Eliakim-Raz</surname> <given-names>N</given-names></name><name><surname>Nutman</surname> <given-names>A</given-names></name><name><surname>Zusman</surname> <given-names>O</given-names></name><name><surname>Antoniadou</surname> <given-names>A</given-names></name><name><surname>Pafundi</surname> <given-names>PC</given-names></name><name><surname>Adler</surname> <given-names>A</given-names></name><name><surname>Dickstein</surname> <given-names>Y</given-names></name><name><surname>Pavleas</surname> <given-names>I</given-names></name><name><surname>Zampino</surname> <given-names>R</given-names></name><name><surname>Daitch</surname> <given-names>V</given-names></name><name><surname>Bitterman</surname> <given-names>R</given-names></name><name><surname>Zayyad</surname> <given-names>H</given-names></name><name><surname>Koppel</surname> <given-names>F</given-names></name><name><surname>Levi</surname> <given-names>I</given-names></name><name><surname>Babich</surname> <given-names>T</given-names></name><name><surname>Friberg</surname> <given-names>LE</given-names></name><name><surname>Mouton</surname> <given-names>JW</given-names></name><name><surname>Theuretzbacher</surname> <given-names>U</given-names></name><name><surname>Leibovici</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial</article-title><source>The Lancet. Infectious diseases</source><volume>18</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30099-9</pub-id><pub-id pub-id-type="pmid">29456043</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietschmann</surname> <given-names>S</given-names></name><name><surname>Hoffmann</surname> <given-names>K</given-names></name><name><surname>Voget</surname> <given-names>M</given-names></name><name><surname>Pison</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Synergistic effects of miconazole and polymyxin B on microbial pathogens</article-title><source>Veterinary research communications</source><volume>33</volume><fpage>489</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1007/s11259-008-9194-z</pub-id><pub-id pub-id-type="pmid">19085068</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirel</surname> <given-names>L</given-names></name><name><surname>Jayol</surname> <given-names>A</given-names></name><name><surname>Nordmann</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes</article-title><source>Clinical microbiology reviews</source><volume>30</volume><fpage>557</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1128/CMR.00064-16</pub-id><pub-id pub-id-type="pmid">28275006</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polverino</surname> <given-names>E</given-names></name><name><surname>Goeminne</surname> <given-names>PC</given-names></name><name><surname>McDonnell</surname> <given-names>MJ</given-names></name><name><surname>Aliberti</surname> <given-names>S</given-names></name><name><surname>Marshall</surname> <given-names>SE</given-names></name><name><surname>Loebinger</surname> <given-names>MR</given-names></name><name><surname>Murris</surname> <given-names>M</given-names></name><name><surname>Cantón</surname> <given-names>R</given-names></name><name><surname>Torres</surname> <given-names>A</given-names></name><name><surname>Dimakou</surname> <given-names>K</given-names></name><name><surname>De Soyza</surname> <given-names>A</given-names></name><name><surname>Hill</surname> <given-names>AT</given-names></name><name><surname>Haworth</surname> <given-names>CS</given-names></name><name><surname>Vendrell</surname> <given-names>M</given-names></name><name><surname>Ringshausen</surname> <given-names>FC</given-names></name><name><surname>Subotic</surname> <given-names>D</given-names></name><name><surname>Wilson</surname> <given-names>R</given-names></name><name><surname>Vilaró</surname> <given-names>J</given-names></name><name><surname>Stallberg</surname> <given-names>B</given-names></name><name><surname>Welte</surname> <given-names>T</given-names></name><name><surname>Rohde</surname> <given-names>G</given-names></name><name><surname>Blasi</surname> <given-names>F</given-names></name><name><surname>Elborn</surname> <given-names>S</given-names></name><name><surname>Almagro</surname> <given-names>M</given-names></name><name><surname>Timothy</surname> <given-names>A</given-names></name><name><surname>Ruddy</surname> <given-names>T</given-names></name><name><surname>Tonia</surname> <given-names>T</given-names></name><name><surname>Rigau</surname> <given-names>D</given-names></name><name><surname>Chalmers</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>European Respiratory Society guidelines for the management of adult bronchiectasis</article-title><source>The European respiratory journal</source><volume>50</volume><elocation-id>1700629</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.00629-2017</pub-id><pub-id pub-id-type="pmid">28889110</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname> <given-names>JP</given-names></name><name><surname>Hancock</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The relationship between peptide structure and antibacterial activity</article-title><source>Peptides</source><volume>24</volume><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2003.08.023</pub-id><pub-id pub-id-type="pmid">15019199</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raetz</surname> <given-names>CR</given-names></name><name><surname>Reynolds</surname> <given-names>CM</given-names></name><name><surname>Trent</surname> <given-names>MS</given-names></name><name><surname>Bishop</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lipid A modification systems in gram-negative bacteria</article-title><source>Annual review of biochemistry</source><volume>76</volume><fpage>295</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.76.010307.145803</pub-id><pub-id pub-id-type="pmid">17362200</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satlin</surname> <given-names>MJ</given-names></name><name><surname>Lewis</surname> <given-names>JS</given-names></name><name><surname>Weinstein</surname> <given-names>MP</given-names></name><name><surname>Patel</surname> <given-names>J</given-names></name><name><surname>Humphries</surname> <given-names>RM</given-names></name><name><surname>Kahlmeter</surname> <given-names>G</given-names></name><name><surname>Giske</surname> <given-names>CG</given-names></name><name><surname>Turnidge</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical and laboratory standards institute and european committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints</article-title><source>Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America</source><volume>71</volume><fpage>e523</fpage><lpage>e529</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa121</pub-id><pub-id pub-id-type="pmid">32052041</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Usongo</surname> <given-names>V</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Colistin induces <italic>S. aureus</italic> Susceptibility to Bacitracin</article-title><source>Frontiers in Microbiology</source><volume>9</volume><elocation-id>2805</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.02805</pub-id><pub-id pub-id-type="pmid">30515145</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname> <given-names>BW</given-names></name><name><surname>Trent</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pushing the envelope: LPS modifications and their consequences</article-title><source>Nature reviews. Microbiology</source><volume>17</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0201-x</pub-id><pub-id pub-id-type="pmid">31142822</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skov</surname> <given-names>RL</given-names></name><name><surname>Monnet</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Plasmid-mediated colistin resistance (<italic>mcr</italic>-1 gene): three months later, the story unfolds</article-title><source>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</source><volume>21</volume><elocation-id>30155</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2016.21.9.30155</pub-id><pub-id pub-id-type="pmid">26967914</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperandeo</surname> <given-names>P</given-names></name><name><surname>Lau</surname> <given-names>FK</given-names></name><name><surname>Carpentieri</surname> <given-names>A</given-names></name><name><surname>De Castro</surname> <given-names>C</given-names></name><name><surname>Molinaro</surname> <given-names>A</given-names></name><name><surname>Dehò</surname> <given-names>G</given-names></name><name><surname>Silhavy</surname> <given-names>TJ</given-names></name><name><surname>Polissi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Functional analysis of the protein machinery required for transport of lipopolysaccharide to the outer membrane of <italic>Escherichia coli</italic></article-title><source>Journal of bacteriology</source><volume>190</volume><fpage>4460</fpage><lpage>4469</lpage><pub-id pub-id-type="doi">10.1128/JB.00270-08</pub-id><pub-id pub-id-type="pmid">18424520</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanford</surname> <given-names>GE</given-names></name><name><surname>Dave</surname> <given-names>K</given-names></name><name><surname>Simmonds</surname> <given-names>NJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape</article-title><source>Chest</source><volume>159</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2020.09.084</pub-id><pub-id pub-id-type="pmid">32966813</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname> <given-names>K</given-names></name><name><surname>Qureshi</surname> <given-names>N</given-names></name><name><surname>Raetz</surname> <given-names>CR</given-names></name><name><surname>Ribi</surname> <given-names>E</given-names></name><name><surname>Peterson</surname> <given-names>J</given-names></name><name><surname>Cantrell</surname> <given-names>JL</given-names></name><name><surname>Pearson</surname> <given-names>FC</given-names></name><name><surname>Wiggins</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>AG</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities</article-title><source>Infection and immunity</source><volume>45</volume><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1128/IAI.45.2.350-355.1984</pub-id><pub-id pub-id-type="pmid">6378795</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>R</given-names></name><name><surname>Velaphi</surname> <given-names>S</given-names></name><name><surname>Ellis</surname> <given-names>S</given-names></name><name><surname>Walker</surname> <given-names>AS</given-names></name><name><surname>Standing</surname> <given-names>JF</given-names></name><name><surname>Heath</surname> <given-names>P</given-names></name><name><surname>Sharland</surname> <given-names>M</given-names></name><name><surname>Dona'</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The use of polymyxins to treat carbapenem resistant infections in neonates and children</article-title><source>Expert opinion on pharmacotherapy</source><volume>20</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1080/14656566.2018.1559817</pub-id><pub-id pub-id-type="pmid">30576264</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname> <given-names>TB</given-names></name><name><surname>Velkov</surname> <given-names>T</given-names></name><name><surname>Nation</surname> <given-names>RL</given-names></name><name><surname>Forrest</surname> <given-names>A</given-names></name><name><surname>Tsuji</surname> <given-names>BT</given-names></name><name><surname>Bergen</surname> <given-names>PJ</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?</article-title><source>International journal of antimicrobial agents</source><volume>48</volume><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.09.010</pub-id><pub-id pub-id-type="pmid">27793510</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trimble</surname> <given-names>MJ</given-names></name><name><surname>Mlynárčik</surname> <given-names>P</given-names></name><name><surname>Kolář</surname> <given-names>M</given-names></name><name><surname>Hancock</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Polymyxin: Alternative Mechanisms of Action and Resistance</article-title><source>Cold Spring Harbor perspectives in medicine</source><volume>6</volume><elocation-id>a025288</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a025288</pub-id><pub-id pub-id-type="pmid">27503996</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velkov</surname> <given-names>T</given-names></name><name><surname>Thompson</surname> <given-names>PE</given-names></name><name><surname>Nation</surname> <given-names>RL</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structure--activity relationships of polymyxin antibiotics</article-title><source>Journal of medicinal chemistry</source><volume>53</volume><fpage>1898</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1021/jm900999h</pub-id><pub-id pub-id-type="pmid">19874036</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Kang</surname> <given-names>M</given-names></name><name><surname>Zong</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of novel mobile colistin resistance gene <italic>mcr-10</italic></article-title><source>Emerging microbes &amp; infections</source><volume>9</volume><fpage>508</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1732231</pub-id><pub-id pub-id-type="pmid">32116151</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname> <given-names>RL</given-names></name><name><surname>Fraser</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>Surface structure of intact cells and spheroplasts of <italic>Pseudomonas aeruginosa</italic></article-title><source>Journal of Bacteriology</source><volume>113</volume><fpage>963</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1128/JB.113.2.963-968.1973</pub-id><pub-id pub-id-type="pmid">4632327</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiegand</surname> <given-names>I</given-names></name><name><surname>Hilpert</surname> <given-names>K</given-names></name><name><surname>Hancock</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances</article-title><source>Nature protocols</source><volume>3</volume><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.521</pub-id><pub-id pub-id-type="pmid">18274517</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>R</given-names></name><name><surname>Taylor</surname> <given-names>RJ</given-names></name><name><surname>Kahne</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Outer Membrane Translocon Communicates with Inner Membrane ATPase To Stop Lipopolysaccharide Transport</article-title><source>Journal of the American Chemical Society</source><volume>140</volume><fpage>12691</fpage><lpage>12694</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b07656</pub-id><pub-id pub-id-type="pmid">30253645</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yapa</surname> <given-names>SWS</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Patel</surname> <given-names>K</given-names></name><name><surname>Wilson</surname> <given-names>JW</given-names></name><name><surname>Dooley</surname> <given-names>MJ</given-names></name><name><surname>George</surname> <given-names>J</given-names></name><name><surname>Clark</surname> <given-names>D</given-names></name><name><surname>Poole</surname> <given-names>S</given-names></name><name><surname>Williams</surname> <given-names>E</given-names></name><name><surname>Porter</surname> <given-names>CJ</given-names></name><name><surname>Nation</surname> <given-names>RL</given-names></name><name><surname>McIntosh</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration</article-title><source>Antimicrobial agents and chemotherapy</source><volume>58</volume><fpage>2570</fpage><lpage>2579</lpage><pub-id pub-id-type="doi">10.1128/AAC.01705-13</pub-id><pub-id pub-id-type="pmid">24550334</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zendo</surname> <given-names>T</given-names></name><name><surname>Yoneyama</surname> <given-names>F</given-names></name><name><surname>Sonomoto</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Lactococcal membrane-permeabilizing antimicrobial peptides</article-title><source>Applied microbiology and biotechnology</source><volume>88</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00253-010-2764-3</pub-id><pub-id pub-id-type="pmid">20645082</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Baidin</surname> <given-names>V</given-names></name><name><surname>Pahil</surname> <given-names>KS</given-names></name><name><surname>Moison</surname> <given-names>E</given-names></name><name><surname>Tomasek</surname> <given-names>D</given-names></name><name><surname>Ramadoss</surname> <given-names>NS</given-names></name><name><surname>Chatterjee</surname> <given-names>AK</given-names></name><name><surname>McNamara</surname> <given-names>CW</given-names></name><name><surname>Young</surname> <given-names>TS</given-names></name><name><surname>Schultz</surname> <given-names>PG</given-names></name><name><surname>Meredith</surname> <given-names>TC</given-names></name><name><surname>Kahne</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors</article-title><source>PNAS</source><volume>115</volume><fpage>6834</fpage><lpage>6839</lpage><pub-id pub-id-type="doi">10.1073/pnas.1804670115</pub-id><pub-id pub-id-type="pmid">29735709</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>White</surname> <given-names>KA</given-names></name><name><surname>Polissi</surname> <given-names>A</given-names></name><name><surname>Georgopoulos</surname> <given-names>C</given-names></name><name><surname>Raetz</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Function of <italic>Escherichia coli</italic> MsbA, an essential ABC family transporter, in lipid A and phospholipid biosynthesis</article-title><source>The Journal of biological chemistry</source><volume>273</volume><fpage>12466</fpage><lpage>12475</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.20.12466</pub-id><pub-id pub-id-type="pmid">9575204</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65836.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Cole</surname><given-names>Philip A</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Gao</surname><given-names>Lianghui</given-names> </name><role>Reviewer</role><aff><institution>Beijing Normal University</institution><country>China</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>van Schaik</surname><given-names>Willem</given-names> </name><role>Reviewer</role><aff><institution>Birmingham University</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The antibacterial mechanism of the cyclic peptide antibiotic colistin has been controversial. This paper is of interest to scientists within the field of antimicrobial discovery, as it implies a major adjustment to our current understanding of colistin's mechanism of action and translates this knowledge to potential therapeutic applications.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by myself. The following individuals involved in review of your submission have agreed to reveal their identity: Lianghui Gao (Reviewer #2); Willem van Schaik (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Summary:</p><p>The submitted manuscript presents an argument for a novel mechanism of action for the antibiotic colistin. The authors suggest that colistin kills bacteria through its action on lipopolysaccharides at the inner membrane. This is primarily supported by MCR-1 mediated colistin resistance conferring resistance only to cell lysis and not to outer membrane permeabilization. The authors extend this hypothesis to suggest that increasing the amount of LPS in the inner membrane should increase susceptibility to colistin. By inhibiting LPS transport with murepavadin, the accumulation of LPS in the cytoplasmic membrane increased. Combinations of colistin and murepavadin act synergistically to improve bacterial lysis and show efficacy in a murine lung infection model.</p><p>Essential Revisions:</p><p>1. Observations demonstrating MCR-1 modification does not impact outer membrane perturbation and provides resistance to colistin induced lysis are supported by MacNair et al. They suggest that strengthened LPS packing provided by mcr-1 could play an important role in reducing the uptake and lytic activities of colistin. The author's should address that decreased colistin uptake could also result in reduced lysis. To support their hypothesis, the relationship between the amount of modified LPS in the inner membrane and resistance to cell lysis could be expanded on. https://www.nature.com/articles/s41467-018-02875-z</p><p>2. The authors use the lack of change in susceptibility of mcr-1 spheroplasts to daptomycin and nisin to support that there is no change to the biophysical properties of the phospholipid bilayer of the cytoplasmic membrane. However, whether the sensitivity of daptomycin and nisin to changes to membrane charge or fluidity remains unclear.</p><p>3. Murepavadin is used to increase LPS at the CM and as interpreted would support the hypothesis. However, it is also possible that in the whole cell assays, the OM disruption of colistin sensitizes the cells to the killing activity of murepavadin. Repeating the assays with a non-lethal OM permeabilizer like polymyxin B nonapeptide would eliminate this possibility and strengthen the authors conclusions.</p><p>4. The authors suggest that mcr-1 provides protection from colistin through the modification of LPS at the inner membrane and that outer membrane modification has no impact on colistin activity. In contrast, it has been demonstrated that mcr-1 decoration is capable of preventing outer membrane perturbation by polymyxin B nonapeptide (https://www.nature.com/articles/nmicrobiol201728). This suggests that modified LPS at both the inner and outer membrane may play a role in resistance.</p><p>5. Authors should discuss work in the synergy between novobiocin and colistin where novobiocin enhances colistin killing through the stimulation of LPS transport. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990483/</p><p>6. Hydrophobic NPN dye was used to explore the permeabilization of OM in this work. However, the uptake of NPN is not absolute proof that colistin is permeable. The authors should discuss this as a possible caveat of their mechanistic model.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65836.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions:</p><p>1. Observations demonstrating MCR-1 modification does not impact outer membrane perturbation and provides resistance to colistin induced lysis are supported by MacNair et al. They suggest that strengthened LPS packing provided by mcr-1 could play an important role in reducing the uptake and lytic activities of colistin. The author's should address that decreased colistin uptake could also result in reduced lysis. To support their hypothesis, the relationship between the amount of modified LPS in the inner membrane and resistance to cell lysis could be expanded on. https://www.nature.com/articles/s41467-018-02875-z</p></disp-quote><p>We thank the reviewers for raising this important point. We agree that it is possible that whilst the OM of <italic>E. colimcr</italic>-1 is permeabilised by colistin, the modified LPS might restrict access of the antibiotic to the periplasm and thereby reduce killing and lysis. We have now made this point clear in the revised manuscript (please see lines: 190-194). However, since much of our data comes from studies with spheroplasts this possibility does not invalidate our findings or conclusion that colistin targets LPS in the CM and that this interaction is required for bacterial killing and lysis of susceptible strains.</p><p>To investigate the relationship between the amount of modified LPS in the inner membrane and resistance, we grew our <italic>E. coli mcr</italic>-1 strain with or without IPTG to modulate the levels of MCR-1 and thus the degree of LPS modification at the CM. We then generated spheroplasts of these bacteria and from <italic>E. coli</italic> pEmpty where none of the LPS is modified and exposed them to colistin. This revealed a clear relationship between the abundance of unmodified LPS in the CM and susceptibility to colistin-mediated permeabilization and lysis (please see Figure 2—figure supplement 2) (please see lines: 216-219).</p><disp-quote content-type="editor-comment"><p>2. The authors use the lack of change in susceptibility of mcr-1 spheroplasts to daptomycin and nisin to support that there is no change to the biophysical properties of the phospholipid bilayer of the cytoplasmic membrane. However, whether the sensitivity of daptomycin and nisin to changes to membrane charge or fluidity remains unclear.</p></disp-quote><p>We agree that this is an important point. To address definitively whether modification of LPS by MCR-1 affects the biophysical properties of the cytoplasmic membrane, we have assessed both membrane fluidity and membrane charge. These assays demonstrate that MCR-1-mediated LPS modification does not affect CM fluidity and has only a slight effect on CM charge, in keeping with the relatively small amount of LPS in the CM (please see Figure 2—figure supplement 1 and lines: 195-201 in the revised manuscript).</p><disp-quote content-type="editor-comment"><p>3. Murepavadin is used to increase LPS at the CM and as interpreted would support the hypothesis. However, it is also possible that in the whole cell assays, the OM disruption of colistin sensitizes the cells to the killing activity of murepavadin. Repeating the assays with a non-lethal OM permeabilizer like polymyxin B nonapeptide would eliminate this possibility and strengthen the authors conclusions.</p></disp-quote><p>To test whether the synergy between colistin and murepavadin is due to OM permeabilization caused by the polymyxin, we undertook two experiments:</p><p>1. As suggested by the reviewers, we have assessed whether murepavadin synergises with polymyxin B nonapeptide in checkerboard assays. By contrast to colistin and murepavadin, which show synergy, murepavadin and polymyxin B nonapeptide were not synergistic (please see Figure 4—figure supplement 5, figure supplement 6).</p><p>2. We pre-treated <italic>P. aeruginosa</italic> with murepavadin alone to cause LPS accumulation in the CM, then removed the murepavadin by washing before exposing the bacteria to colistin alone. The murepavadin-treated cells were much more susceptible to colisitin than untreated cells (please see Figure 4—figure supplement 7).</p><p>Taken together, the data from these two experiments confirm that the synergy observed between murepavadin and colistin is not due to OM permeabilization by the polymyxin antibiotic. Rather, it is due to the murepavadin-mediated accumulation of LPS in the cytoplasmic membrane increasing the susceptibility of bacteria to colistin (please see lines: 295-308).</p><disp-quote content-type="editor-comment"><p>4. The authors suggest that mcr-1 provides protection from colistin through the modification of LPS at the inner membrane and that outer membrane modification has no impact on colistin activity. In contrast, it has been demonstrated that mcr-1 decoration is capable of preventing outer membrane perturbation by polymyxin B nonapeptide (https://www.nature.com/articles/nmicrobiol201728). This suggests that modified LPS at both the inner and outer membrane may play a role in resistance.</p></disp-quote><p>We would like to make clear that we don’t claim that modification of LPS at the OM has no impact on colistin activity, just that it doesn’t prevent permeabilization of the OM, which is in keeping with previous work by Macnair et al., 2018. We have edited the text to make this point clear (please see lines: 190-191).</p><disp-quote content-type="editor-comment"><p>5. Authors should discuss work in the synergy between novobiocin and colistin where novobiocin enhances colistin killing through the stimulation of LPS transport. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990483/</p></disp-quote><p>The revised manuscript now contains a discussion of this work, which shows that increased LPS transport to the outer membrane increases colistin susceptibility (please see lines: 455-466).</p><disp-quote content-type="editor-comment"><p>6. Hydrophobic NPN dye was used to explore the permeabilization of OM in this work. However, the uptake of NPN is not absolute proof that colistin is permeable. The authors should discuss this as a possible caveat of their mechanistic model.</p></disp-quote><p>To confirm the permeabilization of the outer membrane of MCR-1 expressing <italic>E. coli</italic> by colistin, we have confirmed the synergy between colistin and rifampicin in checkerboard assays as described by Macnair et al., 2018. Since rifampicin cannot normally cross the outer membrane, these data and those of Macnair et al., provide additional evidence for outer membrane disruption of <italic>E. coli</italic> MCR-1 cells by colistin (please see lines: 149-155 and Figure 1—figure supplement 6).</p></body></sub-article></article>